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ABSTRACT 
 
THE ASSOCIATION BETWEEN DEPRESSION, ANXIETY AND CLINICAL 
OUTCOMES FOR TYPE 2 DIABETES MELLITUS 
 
 
 
By 
Elham Heidari 
December 2018 
 
Thesis supervised by Dr Jordan Covvey 
Objective: To evaluate the impact of depression and/or anxiety on clinical outcomes of 
diabetes, including glycosylated hemoglobin (HgA1c), blood glucose, blood pressure, 
total cholesterol, weight and LDL among patients with incident type 2 diabetes mellitus 
(T2DM). 
Method: A retrospective cohort study utilizing electronic medical record (EMR) 
data from a primary care physician (PCP) group practice was conducted to identify 
patients newly diagnosed with T2DM with at least 6 months pre-diagnosis and 12 
months post-diagnosis of EMR data using International Classification of Disease 9th 
edition Clinical Modification (ICD-9-CM) coding. The presence of comorbid depression 
and anxiety was identified to identify four cohorts: (1) patients with T2DM only, (2) 
patients with T2DM and depression, (3) patients with T2DM and anxiety, and (4) patients 
with T2DM and depression and anxiety. Data regarding patients’ demographic, clinical 
 v
characteristics, lab results and medication utilization during the first year following 
diagnosis of T2DM (the index date) were gathered. Analyses included comparison of 
patients’ demographics and clinical characteristics (using matching), evaluation of 
clinical outcomes of diabetes with regard to mental illness diagnosis, and examination of 
mental illness treatment and mental illness severity. Finally, factors predicting HgA1c 
goal attainment were assessed via the use of a logistic regression model. 
Result: The inclusion/exclusion criteria led to a study sample of 1822 T2DM patients 
amongst whom 1410 had T2DM only, 148 had T2DM and concomitant depression, 215 
had T2DM and concomitant anxiety, 49 had T2DM and both depression and anxiety. 
Significant reductions in HgA1c occurred across all four groups from baseline to follow-
up (p<0.05), however blood pressure was the only outcome differing across the cohorts, 
related to being diagnosed with depression and anxiety. Severity and prescription of 
antidepressant did not render significant changes in the pattern of clinical outcomes. The 
results of logistic regression indicated that age at index, HgA1c at index and number of 
diabetes medications along with being diagnosed with mental illness were significant 
predictors of HgA1c goal attainment. 
Conclusion: The findings suggest that comorbid depression and/or anxiety have limited 
singular influence upon clinical outcomes of diabetes among patients with T2DM. 
Further work should examine additional clinical outcomes for diabetes and model the 
influence of demographic and clinical contributors to these outcomes. Limitations of the 
study include generalizability, degree of missing data, lack of information on other 
potentially influential predictors, misclassification bias and reliability of coding utilized 
to isolate study sample.  
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“The aim (of treatment) is to relieve people of their neurotic unhappiness so that they can 
be normally unhappy.” 
 
Sigmund Freud 
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CHAPTER ONE – INTRODUCTION 
 
I. Diabetes 
Diabetes mellitus (DM) is a common metabolic disorder which has become a major public health 
problem worldwide. In general, DM refers to a group of diseases that affect glucose regulation in 
the blood. It is primarily categorized into two different forms: type 1 and type 2. Type 1 diabetes 
mellitus (T1DM) is a chronic condition in which the pancreas produces little or no insulin, often 
diagnosed at a young age and requiring life-long exogenous insulin. Type 2 diabetes mellitus 
(T2DM) occurs when the body either doesn't produce enough insulin, or has developed resistance 
to insulin. Among the two main categories, T2DM, also known as non-insulin-dependent diabetes 
mellitus (NIDDM), is more common, accounting for over 90% of diabetes diagnoses in the United 
States (USA), Canada, and Europe, particularly among older and urban populations.1 Due in part 
to the trends in obesity and sedentary lifestyle,2 the prevalence of T2DM has increased alarmingly 
over the past decades in both developed and developing nations.3 
a. Pathophysiology 
Several factors are involved in the pathogenesis of T2DM, rendering prevention and treatment 
complicated.4 Patients present with a combination of varying degrees of insulin resistance and 
relative insulin deficiency, and it is likely that both contribute to T2DM.5-7 The presence of insulin 
resistance explains the strong clinical association of T2DM with obesity and other insulin-resistant 
states. Impaired insulin secretion has been demonstrated in a variety of studies, which show that 
both adolescents and adults usually have lost about 80% of their pancreatic beta cell function 
before the diagnosis of T2DM.8,9 In most cases, the pancreatic dysfunction does not appear to be 
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mediated by antibodies against the pancreatic islet cells. Furthermore, each of the clinical features 
can arise through genetic or environmental influences, making it difficult to determine the exact 
cause in an individual patient. Moreover, hyperglycemia itself can impair pancreatic beta-cell 
function and exacerbate insulin resistance, leading to a vicious cycle of hyperglycemia causing a 
worsening metabolic state.10 T2DM is often accompanied by other conditions, including 
hypertension and hyperlipidemia (high serum low-density lipoprotein [LDL] cholesterol and low 
serum high-density lipoprotein [HDL] cholesterol concentrations) that further increase 
cardiovascular risk. This constellation of clinical conditions is referred to as the metabolic 
syndrome.11 Hyperinsulinemia occurring in response to insulin resistance may play an important 
role in the genesis of these abnormalities. Increased free fatty acid levels, inflammatory cytokines 
from fat, and oxidative factors have all been implicated in the pathogenesis of metabolic syndrome, 
T2DM, and their cardiovascular complications. 
b. Prevalence and impact 
Almost 285 million people are suffering from DM worldwide, rising to 438 million by the year 
2030.12 Worldwide, the prevalence of T2DM is estimated at 6.4% among adults, varying from 3.8 
to 10.2% by region, with rates of undiagnosed DM as high as 50% in some areas.13  
 
According to Centers for Disease Control and Prevention (CDC), T2DM is the seventh leading 
cause of death in the USA and affects more than 30.3 million people or 9.4% of the total 
population.14 In the US, the overall prevalence of T2DM ranges from 12 to 14%, depending on the 
criteria employed using the hemoglobin A1c (HgA1c), fasting blood glucose (FBG), or 2-hour 
blood glucose (BG) definitions for DM and prediabetes.15 Estimates from the CDC are slightly 
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lower, with the overall prevalence of DM among adults in the USA ranging from 5.8 to 12.9%, 
with a median of 8.4%.16 An analysis of data from the National Health Interview Survey (NHIS) 
found a doubling in the prevalence of T2DM from 1990 to 2008, with no significant change during 
2008 to 2012.17 Other national databases, such as the National Health and Nutrition Examination 
Survey (NHANES), have reported an increase in the prevalence of DM over two decades (from 
9.8 to 12.4%), and have confirmed the relatively stable prevalence between 2008 and 2012.18 
Given the marked increased in the prevalence of childhood obesity, there is concern that the 
prevalence of DM may increase over time. 
 
The prevalence of T2DM varies among certain populations. According to the CDC, among adults 
over 20 years of age, the national prevalence of T2DM from 2010 to 2012 was 7.6% in non-
Hispanic whites, 9.0% in Asian Americans, 12.8% in Hispanics, 13.2% in non-Hispanic blacks, 
and 15.9% in American Indians/Alaska Natives. In an analysis of data from the Behavioral Risk 
Factor Surveillance System (BRFSS) from 2011 to 2014, the prevalence of self-reported DM was 
higher among Asians (9.9%) and Native Hawaiians or other Pacific Islanders (14.3%) than in 
Caucasian individuals (8.0%).19  
 
Numerous factors, in addition to directly related medical complications, contribute to the impact 
of DM on quality of life and costs. People with DM are two to four-fold more likely to suffer 
strokes and heart disease, and are more likely to die from these conditions. Other DM-related 
complications such as retinopathy, kidney failure, and neuropathy further contribute to decreases 
in health-related quality of life. In addition, patients with DM require self-care, including blood 
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glucose concentration monitoring, foot examinations, management of multiple medications, 
regular exercise, and diet restrictions; these requirements also affect health-related quality of life.20  
 
The total direct and indirect estimated cost of diagnosed DM in the USA in 2012 was $245 billion. 
Average medical expenditures for people with diagnosed DM were about $13,700 per year, with 
approximately $7,900 of this amount attributed to DM.21 After adjusting for age and sex, average 
medical expenditures among people with diagnosed DM were about 2.3 times higher than 
expenditures for people without DM.21 Overall, DM was recognized as the seventh leading cause 
of death in the USA in 2015, incurring the highest personal healthcare spending compared to any 
other condition. 22 
c. Screening and diagnosis 
A consensus statement regarding the management of hyperglycemia in T2DM by the American 
Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) was 
developed in 2006 and has been updated regularly.23 Clinical management of T2DM in the USA 
commonly utilizes the ADA guidelines, which are published and updated yearly. An additional 
available guideline is also available from the American Association of Clinical Endocrinologists 
and American College of Endocrinology for the comprehensive management of persons with 
T2DM. This algorithm was developed to provide clinicians with a practical guide that considers 
the patient, their spectrum of risks and complications, and evidence-based approaches to 
treatment.24 It is more commonly utilized by endocrinologists, while the ADA guidelines tends to 
be favored in primary care. 
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A number of reliable laboratory tests are available for the screening and diagnosis of DM. Tests 
that can be used to screen for T2DM are measurement of HgA1c, FBG, and a two-hour BG during 
an oral glucose tolerance test (OGTT). However, because of its inconvenience, OGTT is not 
commonly used for screening, except in pregnant women. The 2006 World Health Organization 
(WHO) criteria define DM as a FBG ≥126 mg/dL (7.0 mmol/L) or a two-hour post-OGTT value 
≥200 mg/dL (11.1 mmol/L). In 2011, the WHO concluded that a HgA1c value of ≥6.5% 
(48 mmol/mol) can also be used as a diagnostic test for DM; however, a value of <6.5% does not 
exclude DM.25 Impaired glucose tolerance (IGT) is defined as a FBG <126 
mg/dL (7.0 mmol/L), and a two-hour post-OGTT glucose ≥140 mg/dL (7.8 mmol/L) but 
<200 mg/dL (11.05 mmol/L). Impaired fasting glucose (IFG) is defined as a FBG of 110 to 
125 mg/dL (6.1 to 6.9 mmol/L). 
 
In 2003, the ADA recommended the use of FBG levels (established through no caloric intake for 
at least eight hours) or 75g OGTT for diagnosing DM.26 In 2009, an International Expert 
Committee recommended using a HgA1c value of ≥6.5% (≥48 mmol/mol) for diagnosis,27 and the 
ADA/EASD and WHO affirmed the decision.28 The following definitions are from ADA 
guidance:13,29 
 Normal: 
o FPG <100 mg/dL (5.6 mmol/L), or 
o Two-hour post-OGTT <140 mg/dL (7.8 mmol/L) 
 Increased risk for DM: 
o IFG – FPG 100-125 mg/dL (5.6-6.9 mmol/L) 
o IGT – Two-hour post-OGTT 140-199 mg/dL (7.8-11.0 mmol/L) 
o HgA1c –5.7-6.4% (39-46 mmol/mol)  
 DM: 
o FPG ≥126 mg/dL (7.0 mmol/L), HgA1c ≥6.5% (48 mmol/mol), a two-hour post-
OGTT ≥200 mg/dL (11.1 mmol/L), or a random BG ≥200 mg/dL (11.1 mmol/L) 
in the presence of symptoms 
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There has been longstanding interest in the use of HgA1c values for screening and identification 
of impaired glucose regulation.30 HgA1c values were not previously recommended to diagnose 
DM due to variation in assays. However, the National Glycohemoglobin Standardization Program 
(NGSP) has standardized more than 99% of the assays used in the USA to the Diabetes Control 
and Complications Trial (DCCT) standard. There are also several technical advantages of a HgA1c 
measurement over BG testing, increased patient convenience (since there is no special preparation 
or timing required for a HgA1c test), and the correlation of HgA1c levels with mean glucose 
concentrations and DM complications.26 
d. Treatment 
Current pharmacologic treatments for T2DM are based upon increasing the availability of insulin 
(either through direct administration or through agents that promote insulin secretion), improving 
sensitivity to insulin, delaying the delivery and absorption of carbohydrates from the 
gastrointestinal tract, or increasing urinary glucose excretion. Non-pharmacologic treatment 
primarily includes weight reduction, exercise and dietary modification.  
 
According to ADA/EASD, early initiation of treatment for T2DM, before the HgA1c is not 
substantially elevated, is associated with improved glycemic control over time and decreased long-
term complications.31 Pharmacologic therapy started with delay may result in increased difficult 
achieving glycemic control. For most patients presenting with HgA1c at or above target level (>7.5 
to 8.0%), pharmacologic therapy should be initiated at the time of DM diagnosis. For highly 
motivated patients with HgA1c near target (<7.5%), a three- to six-month trial of lifestyle 
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modification before initiating pharmacologic therapy is reasonable. In selecting initial therapy, 
patient presentation (eg, presence or absence of symptoms of hyperglycemia and comorbidities, 
baseline HgA1c level), individualized treatment goals, and the glucose-lowering efficacy of 
individual drugs are important factors to consider. The majority of patients with newly diagnosed 
T2DM are asymptomatic, and hyperglycemia is noted on routine laboratory evaluation.23,32 
 
For patients with HgA1c <7.6% or close to (eg, >0.5 to 1.5% above) treatment goal, in the absence 
of specific contraindications, metformin is suggested as initial therapy in most patients at the time 
of DM diagnosis, along with consultation for lifestyle intervention. It is usually initiated as 500 
mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast. 
The dose can be increased slowly (one tablet every one to two weeks) as necessary. Metformin is 
chosen for initial therapy because of glycemic efficacy, absence of weight gain and hypoglycemia, 
general tolerability and favorable cost. For asymptomatic patients with HgA1c relatively far from 
goal (8.5 to 9.5%), metformin is still suggested to be the choice for pharmacotherapy initiation. 
Insulin also can be considered a first-line therapy for patients, particularly presenting with HgA1c 
relatively far from goal (>9%).  
 
For patients with contraindications to metformin, other options for initial therapy are available, 
including (1) a shorter-acting sulfonylurea, such as glipizide (inclusive of lifestyle intervention 
initiation, since the weight gain that often accompanies a sulfonylurea will presumably be less if 
lifestyle efforts are underway), (2) repaglinide or pioglitazone, if patients are intolerant of or are 
not candidates for metformin or sulfonylureas, or (3) other oral and injectable agents, such as 
glucagon-like peptide-1 (GLP-1) agonists, alpha-glucosidase inhibitors, sodium-glucose co-
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transporter 2 (SGLT-2) inhibitors, or dipeptidyl peptidase-4 (DPP-4) inhibitors, which may be 
appropriate initial therapy for some patients.23,32 
 
Although efforts to diagnose DM earlier have improved, patients may present with symptomatic 
or severe hyperglycemia. Insulin, rather than oral hypoglycemic agents, is often indicated for 
initial treatment of symptomatic or severe hyperglycemia (FBG >250 mg/dL, random BG 
consistently >300 mg/dL, HgA1c >9.5%). Insulin therapy in T2DM is initially aimed at increasing 
basal insulin concentrations, and patients with T2DM require relatively large doses of insulin 
compared with those needed for T1DM.  
e. Treatment goals 
The main goal in treatment is achieving glycemic targets and minimizing adverse effects. Target 
HgA1c levels in patients with T2DM should be tailored to the individual, balancing the 
improvement in microvascular complications with the risk of hypoglycemia. A reasonable goal of 
therapy is a HgA1c of ≤7.0% for most patients. In order to achieve the HgA1c goal, a FBG of 80-
130 mg/dL (4.4-7.2 mmol/L) and a postprandial BG (90-120 minutes after a meal) <180 mg/dL 
(10 mmol/L) are usually necessary.33 
 
Good glycemic control improves the risk of microvascular complications in patients with T2DM. 
Every 1.0% drop in HgA1c is associated with improved outcomes.27 HgA1c goals in patients with 
T2DM should be tailored to the individual, balancing the improvement in microvascular 
complications with the risk of hypoglycemia. Glycemic targets are generally set somewhat higher 
for older adult patients, those with comorbidities, or those with limited life expectancy and little 
likelihood of benefit from intensive therapy.  
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In addition to glycemic control, vigorous cardiac risk reduction (smoking cessation, aspirin, blood 
pressure and lipid control, diet and exercise) should be a top priority for all patients with T2DM. 
However, in spite of evidence that aggressive risk factor reduction lowers the risk of both micro- 
and macrovascular complications in patients with DM, many patients do not achieve recommended 
goals for HgA1c, blood pressure control, and management of hyperlipidemia.  
f. Complications of diabetes 
Hyperglycemia is an important risk factor for the development of microvascular disease in patients 
with T2DM, which has been demonstrated in several observational studies.34 In addition, 
improving glycemic control improves microvascular outcomes, as illustrated by the findings of a 
meta-analysis of randomized trials inclusive of nearly 35,000 patients.35 There was a reduction in 
the risk of microvascular complications (a composite outcome including progression of 
nephropathy, manifestation and progression of retinopathy, and retinal photocoagulation) in the 
intensive compared with standard glycemic control group (relative risk [RR]: 0.88, 95% CI 0.82-
0.95). In other meta-analyses of trials (over 28,000 adults) evaluating the benefits of intensive 
versus conventional glycemic control specifically on renal outcomes, there was a statistically 
significant reduction in the risk of microalbuminuria and macroalbuminuria in patients randomly 
assigned to intensive glycemic control (RR: 0.86 and 0.74, respectively).36,37  
 
Epidemiologic analyses (observational studies or secondary analyses of trials) suggest a 
correlation between higher rates of cardiovascular disease (CVD) and chronic hyperglycemia.38,39 
As an example, in a meta-analysis of 13 prospective cohort studies (10 in T2DM, including the 
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United Kingdom Prospective Diabetes Study [UKPDS]), for every percentage point increase in 
HgA1c, the RR for any cardiovascular event was 1.18 (95% CI 1.10-1.26).18 The most effective 
approach for prevention of macrovascular complications appears to be multifactorial risk factor 
reduction (glycemic control, stopping smoking, aggressive blood pressure control, treatment of 
dyslipidemia, and for secondary prevention, daily aspirin). 
 
In T2DM, disease onset is insidious, and diagnosis is often delayed. As a result, diabetic 
complications may be present at the time of diagnosis of DM,40 and their frequency increases over 
time. Once present, the progression of these complications can be slowed with interventions such 
as aggressive management of glycemia, blood pressure and lipids; administration of an 
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for 
nephropathy. These interventions appear to be reducing the incidence of several DM-related 
complications, including myocardial infarction (MI), stroke, lower-extremity amputation, and end-
stage renal disease (ESRD). In the US, the greatest absolute declines have been reported for acute 
DM-related MI and stroke (between 1990 and 2010, 95.6 and 58.9 fewer cases per 10,000 persons 
per year, respectively).41 
 
Adults with T2DM are at risk for obesity, hypertension, and dyslipidemia. However, there are 
other comorbidities as well. These disorders, which may be present at diagnosis or may develop 
over time, include hearing impairment, sleep apnea, fatty liver disease, periodontal disease, 
cognitive impairment, depression, anxiety, and fractures. For patients with signs or symptoms of 
these conditions, additional assessment is warranted.  
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II. Depression 
Major depressive disorder (MDD), commonly referred as unipolar depression, is a prevalent and 
disabling disease. Characteristics of MDD include depressed mood, loss of interest in activities, 
changes in appetite, trouble sleeping, fatigue, restlessness, decreased concentration, and thoughts 
of suicide.42 MDD is ranked as 11th greatest cause of disability and mortality across the globe,43 
and based on estimates from the Global Burden of Disease Study of 2013, approximately 253 
million people globally were found to be affected by MDD.42,44 In the US, MDD is the most 
common mental illness and ranked as second cause of disability among all diseases and injuries. 
a. Pathophysiology 
It is difficult to elucidate the pathophysiology of depression because of the clinical and etiological 
heterogeneity of MDD. Current neurobiological theories are based on studies investigating 
psychosocial stress and stress hormones, neurotransmitters such as serotonin, norepinephrine, 
dopamine, glutamate and gamma-aminobutyric acid (GABA), neurocircuitry, neurotrophic 
factors, and circadian rhythms.45 MDD occurs more often in patients with specific risk factors.46 
These multiple, interacting factors constitute three broad pathways for developing the illness: (1) 
internalizing factors including genetics, low self-esteem, early-onset anxiety disorder, past history 
of MDD, (2) externalizing factors including genetics, substance misuse, conduct disorder, and (3) 
adversity including trauma during childhood or adulthood, stressful life events in past year, 
parental loss or low parental warmth, history of divorce/marital problems, low social support, and 
low education. Parental-related adversity may be specifically due to parental mental illness, 
substance abuse, and criminality. 
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b. Prevalence and impact 
According to community surveys in 14 countries, the estimated life prevalence of unipolar MDD 
is 12%.43 Based upon a systematic review conducted on cost of illness studies of depression 
worldwide, the average annual cost per case ranged from $1000 to $2500 for direct costs, and from 
$2000 to $3700 for morbidity and from $200 to $400 for mortality.47 According to estimates from 
the National Institute of Mental Health (NIMH), 16.1 million or 6.7% of the US population aged 
19 or older suffer from MDD and it accounts for 3.7% of all US disability-adjusted life years 
(DALYs), the highest among mental disorders. The annual cost of illness in the USA is 
approximately $210.5 billion with 45-47% accounting for direct costs, 48-50% accounting for loss 
of productivity, and 5% to suicide-related costs.48 
c. Screening and diagnosis  
The diagnosis of MDD is guided by the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5). MDD is diagnosed in patients who have suffered at least one major 
depressive episode and have no history of mania or hypomania.43 It is usually diagnosed with the 
following symptoms: insomnia or hypersomnia, feelings of worthlessness or excessive guilt, 
fatigue or loss of energy, diminished ability to think or concentrate, substantial change in appetite 
or weight, psychomotor agitation, and recurrent thoughts of death or suicide.49 However the 
severity, duration, and frequency of MDD symptoms are not the same among patients and can vary 
according to the individual patient and also depend on the stage of the illness. In addition, major 
depression is highly recurrent. Following recovery from one episode, the estimated rate of 
recurrence over two years is greater than 40%; after two episodes, the risk of recurrence within 
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five years is approximately 75%.43 There is also treatment resistant and atypical depression and 
depression is also misdiagnosed as bipolar. 
 
Many studies describe treatment outcome using the terms “response” and “remission” following 
the level of improvement from baseline on a clinician-administered depression rating scale. 
Response is defined as improvement greater than 50% but less than the threshold for remission 
while remission is defined as depression rating scale score less than or equal to a specific cutoff 
that defines the normal range.  
d. Treatment 
Initial treatment for MDD is suggested to be a combination of pharmacology and psychotherapy.50 
Lifestyle changes such as relaxation, physical activity and diet change are also recommended to 
help counteract the symptoms of MDD.51 Medication options for patients with MDD include 
selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors 
(SNRIs), bupropion, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors 
(MAOIs).52 Medication choice is based on patient preference, history of prior medication, safety, 
tolerability, side effects, and cost. For the initial treatment of depression, SSRI or SNRI is often 
recommended.53  
 
Antidepressant combinations are generally used for MDD that is resistant to treatment with 
antidepressant monotherapy. Add-on pharmacotherapy is often necessary because initial treatment 
with a single antidepressant leads to remission in only 30 to 50% of patients.54,55 Hence, combining 
antidepressant treatment is common. Generally, MAOIs are only prescribed to patients who have 
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not responded to previous medications.56 TCAs and MAOIs are first generation medications that 
enhance the body’s serotonin and norepinephrine production mechanism but also block histaminic 
and cholinergic receptors sites, often resulting in a number of undesirable adverse effects. SSRIs 
and SNRIs are newer generation antidepressants that target specific brain receptor sites therefore 
resulting in less unwanted side effects.57 Literature indicates psychotherapy is as effective as 
medication for mild to moderate depression and psychotherapy and medication is more effective 
than either alone. 
III. Anxiety 
Generalized anxiety disorder (GAD) is a chronic mental illness characterized by excessive and 
persistent worrying that is hard to control, causes significant distress or impairment, and occurs on 
more days than not for at least six months. Other features include psychological symptoms of 
anxiety, such as apprehensiveness and irritability, and physical (or somatic) symptoms of anxiety, 
such as increased fatigue and muscular tension. Due to the severe symptoms of GAD, patients 
usually struggle with holding a job or completing everyday activities.58 GAD can lead to 
significant impairments in role functioning, diminished quality of life, and high healthcare costs.59 
a. Pathophysiology 
Genetic factors appear to predispose individuals to the development of GAD. GAD shares a 
common heritability with MDD46 and with the personality trait of “neuroticism” in old 
psychology.60 The serotonin transporter gene-linked polymorphic region SS 
genotype (short/short) has been found to be more frequent in patients with GAD. Variations in two 
sub-types of the glutamic acid decarboxylase gene may increase individual susceptibility to 
anxiety disorders, including GAD.61 
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A study of positron emission tomography (PET) scans in patients with GAD demonstrated a 
relative increase in glucose metabolism in parts of the occipital, right posterior temporal lobe, 
inferior gyrus, cerebellum and right frontal gyrus, and an absolute decrease in the basal ganglia: 
benzodiazepine administration was associated with decreases in absolute metabolic rates for 
cortical surface, limbic system and basal ganglia, but was not associated with normalization of 
patterns of glucose metabolism.62 A functional MRI study found increased post cue anticipatory 
activity bilaterally in the dorsal amygdala, after cues indicating forthcoming neutral and aversive 
pictures, providing evidence of overall enhanced anticipatory emotional responsiveness in GAD.63 
Investigations of the processing of emotional information suggest that GAD may be associated 
with specific biases for mood-congruent information.64 Patients with GAD have been found to 
allocate extensive attentional resources to threatening stimuli, detect “threats” rapidly and 
effectively,65 and misinterpret ambiguous information as being threatening.66 GAD in adult life is 
associated with a higher-than-average number of traumatic experiences and other undesirable life 
events in childhood, compared to individuals without GAD.67 GAD is more likely to occur in 
people with “behavioral inhibition,” which is the tendency to be timid and shy in novel situations.68 
Many explanations of the origin and persistence of the excessive and pervasive worrying that 
characterize GAD have been proposed.  
b. Prevalence and impact 
GAD is a prevalent disease in both community and clinical setting. A cross-sectional study 
conducted in 26 countries found combined lifetime GAD prevalence of 3.7%, 12-month 
prevalence of 1.8%, and 30-day prevalence of 0.8% varying widely across countries.69 A review 
of epidemiological studies in Europe reported a 12-month prevalence of 1.7 to 3.4 %, and a lifetime 
prevalence of 4.3 to 5.9%.70 In the US, a lifetime prevalence of GAD in a nationally representative 
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sample is 5.1%71,72 to 11.9%.73 It estimated that the lifetime prevalence of GAD in the USA is 
4.3% and the twelve-month prevalence is 2.0%.74 In general, GAD is twice likely to affect females 
than males71 and probably the most common mental illness among the elderly.75 GAD also has a 
high economic burden on patients worldwide, with a mean annual direct medical cost for a patient 
with GAD estimated at $6,475.76 
c. Screening and diagnosis 
According to the DSM-5, a diagnosis of GAD requires a patient to have excessive anxiety on the 
majority of the days for at least six months, difficulty controlling their worrying, and three or more 
of the following symptoms; restlessness, fatigue, difficulty concentrating, irritability, muscle 
tension, and sleep disturbance.77  
 
GAD is most often found with an adult onset and chronic course.78 The diagnosis of GAD in 
elderly individuals can be challenging due to the common co-occurrence of long-term physical 
illnesses, chronic insomnia, cognitive impairment, and the side effects of prescribed medication. 
Elderly patients with GAD may assert that anxiety or fear is a realistic response to their social 
environment, recent life events and current challenges. Also, anxiety can be brought on by other 
physical health conditions such as hyperthyroidism or hypoglycemia. Certain medications may 
result in anxiety as a side effect. Other untreated mental illnesses such as obsessive-compulsive 
disorder (OCD) and MDD can also increase a patient’s anxiety level. 
 
The Generalized Anxiety Disorder 7-item scale (GAD-7) is the most commonly used screening 
tool that helps indicate whether or not a patient requires a complete clinical assessment for GAD.58 
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The GAD-7 assesses the frequency of common symptoms over the past two weeks, ranging from 
symptoms are not present at all to symptoms are present nearly every day. 
d. Treatment 
GAD can be effectively treated with cognitive-behavioral therapy (CBT), medication, or a 
combination of the two modalities.79 Stress management, meditation, and support groups have also 
been shown to help alleviate the symptoms of GAD. Anti-anxiety medications are used to reduce 
the symptoms of GAD including excessive anxiety, panic attacks, and extreme fear and worry, but 
they do not cure the disorder itself. First-line medications include SSRI and SNRI because they 
offer the best combination of efficacy and safety among all the medications available.80 
Benzodiazepines are the other anti-anxiety medications for GAD that are usually utilized in 
combination with other antidepressants and should only be used short-term due to their high 
potential of dependence and abuse. They treat GAD by inducing relaxation in the patient and 
reducing muscular tension. Finally, beta-blockers can be prescribed to help relieve the physical 
symptoms of GAD such as rapid heartbeat, shaking, and trembling. 
 
IV. Depression and anxiety among people with type 2 diabetes 
a. Depression among people with type 2 diabetes 
DM is associated with a high prevalence of depression81 and adversely impacts employment, 
absenteeism, and work productivity.82 MDD is one of the most prevalent comorbidities among 
patients with T2DM.83 Indeed, the prevalence of MDD is two to three times higher in patients with 
T2DM compared to the general population.84 MDD can enhance the risk of DM-related 
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complications due to reduced treatment adherence, poor self-care and poor glycemic control.85 
Accordingly, routine screening of depression in adults with DM is recommended by the AACE.86 
 
Based on a meta-analysis of 15 studies published before January 2000, the overall prevalence of 
depression in patients with T2DM was 27%.87 A later meta-analysis of 10 studies, based on a total 
of 51,331 people across multiple countries (including the US), reported an overall depression 
prevalence of 17.6% in people with T2DM, compared with 9.8% in those without T2DM.88 A 
study of the 2006 Behavioral Risk Factor Surveillance System (BRFSS) reported depression 
prevalence of 24% in people with T2DM using insulin, and 17.3% in people with T2DM not using 
insulin (depression was defined as total score ≥10 on the Patient Health Questionnaire, PHQ-8).89 
Based on a study using NHANES (2005-2012) data, the overall prevalence of clinically relevant 
depression and clinically significant depression among people with T2DM is 10.6%, and 4.2%, 
respectively.90 
 
Epidemiological studies suggest that the relationship of T2DM and MDD is bidirectional; DM 
increases the risk of depression87 and conversely, MDD increases the risk of development of 
T2DM.91 In a prospective observational study of people 65 years and older who were followed for 
up to 10 years, depressed individuals were more than twice as likely to develop DM compared 
with those without depression, regardless of antidepressant treatment (hazard ratio [HR]: 2.3, 95% 
CI: 1.3-4.1).92 The high prevalence of depression among patients with T2DM indicates the unmet 
need for further longitudinal follow-up for depression in people with T2DM to understand real 
world effectiveness of depression management.90 
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b. Anxiety among people with type 2 diabetes 
Anxiety (GAD and other associated disorders) is also a prevalent mental illness among patients 
with T2DM.93 Results from a meta-analysis conducted support that T2DM is associated with an 
increased likelihood of having an anxiety disorder and/or elevated anxiety symptoms.94 A study 
conducted on patients with T2DM in tertiary care center reported that a significantly larger 
proportion of diabetic patients had depression (26.3% vs. 11.2%, p=0.001), anxiety (27.6% vs. 
12.7%, p=0.001) and comorbid depression and anxiety (21.0% vs. 7.3%, p=0.001) as compared to 
healthy controls, with a higher prevalence in women than men.95 The rates for depression 
and anxiety were 48.27% (95% CI: 44.48-52.06%) and 55.10% (95% CI: 51.44-58.93%), 
respectively in a Mexican population of patients with T2DM.96 In general, patients with 
comorbidity of T2DM and depression or anxiety are suspected to have poorer clinical outcomes 
because of less adherence on oral hypoglycemic medication and in general less self-care behaviors 
or other biologic reasons. 
V. Problem Statement 
As mental illness is gaining more importance in clinical care, we seek to understand the impact of 
depression and anxiety, as two of the most common mental disorders, on the clinical outcomes of 
the disease in patients with T2DM.  
VI. Hypothesis 
The overall hypothesis of the study is that patients with T2DM with comorbidity of depression 
and/or anxiety are at higher risk of failing to meet therapeutic goals for the disease. 
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VII. Research objectives 
In order to examine the influence of comorbid depression and anxiety upon outcomes for patients 
with T2DM, the following research objectives (ROs) are proposed: 
 RO 1: Define the demographics and clinical characteristics of patients with T2DM 
with/without comorbid depression/anxiety  
 RO 2: Assess the influence of the timeline of comorbid depression/anxiety diagnoses 
upon clinical outcomes for T2DM  
 RO 3: Assess the influence of the severity of comorbid depression/anxiety diagnoses and 
receiving antidepressants upon clinical outcomes for T2DM  
 RO 4: Analyze potential predictors of treatment success for patients with T2DM  
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CHAPTER TWO – LITERATURE REVIEW 
 
I. Introduction 
DM is a costly and prevalent disease worldwide, with T2DM representing the majority of patients. 
Due to the trends in daily lifestyle,2 prevalence of DM is elevated thus the prevalence of depression 
among patients with T2DM is also relatively high.97 Although such prevalence varies between 
studies, recent estimates suggest that around 20% (10-30%) of individuals with T2DM suffer from 
depression and anxiety.98,99 The combination of both T2DM and depression/anxiety amplifies the 
risk of failure in therapeutic goal achievement. One potential reason can be the fact that patients 
with depression and/or anxiety are at a higher risk of nonadherence to their medication. Poor 
medication adherence is associated with negative health outcomes in many chronic diseases 
including DM and depression.100-102 The initial approach in treatment of MDD and/or GAD in 
patients with DM would be antidepressant and pharmacotherapy. Antidepressant usage has risen 
sharply in patients with T2DM,103 calling into question the intervening effects on glucose 
metabolism. However, there is a currently incomplete research understanding of exactly how usage 
of antidepressant affects T2DM outcomes.  
II. Objectives 
The aim of the literature review was (1) to assess the impact of antidepressant utilization on clinical 
outcomes of adult patients with T2DM and (2) identify gaps in the existing literature.  
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III. Methods 
Broadly, the aim of a systematic review is to structure the findings of several studies that address 
the same topic, using strategies that restrict bias and random error. The systematic literature review 
was conducted according to the Preferred Reported Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines using three databases (PsycINFO, PubMed, and SCOPUS) to 
identify relevant articles through December 2017. Articles that were not available online were 
requested and received through the Duquesne University Gumberg Library. Article eligibility 
assessment was performed independently by one reviewer and uncertainty about an article’s 
eligibility was resolved by a consensus between the reviewer and the thesis committee chair. 
Controlled search terminology included ‘diabetes mellitus’ in combination with ‘antidepressant,’ 
‘blood glucose,’ ‘hemoglobin A1c,’ ‘fasting blood glucose,’ and related terms. Relevant studies 
assessing the effect of antidepressant therapy upon glucose-related outcomes were included. The 
key outcome evaluated was the overall influence of antidepressant therapy upon HgA1c or FBG.  
a. Inclusion and exclusion criteria 
The studies were included in the review if they evaluated clinical variations in attaining HgA1c or 
FBG goals for adult patients with T2DM who take antidepressants. This was chosen as 
antidepressants represent a common treatment modality between depressive and anxiety disorders. 
The inclusion of articles was limited to patients with T2DM; studies on patients with T1DM or 
only mentioning DM in general were excluded. In addition, included studies focused on the adult 
patient population receiving pharmacological antidepressant treatment; studies focusing on any 
non-pharmacological interventions or with no indication of pharmacological treatment were 
excluded, as well as studies in pediatric patients. Also excluded from the review were non-English 
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studies, non-human studies, grey literature, case reports, review article, conference abstracts, 
dissertations, commentaries, editorials, or summary reports. The final summary of included articles 
is available in Figure 1. 
b. Data extraction 
For the studies evaluating antidepressant usage on clinical outcomes of DM, the following 
information was collected: location, study setting, patient population, type of intervention, duration 
of study, study design, and measurement of outcomes. In addition, information on pharmacologic 
treatment, including type of medication and dose of medications and comparison arm if any, was 
also collected. 
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Figure 1: PRISMA diagram of methodology used and selection criteria 
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IV. Results 
a. Overall findings 
Among 990 articles identified via the search, 25 studies were included in the final review (Table 
1). The publication dates of the articles ranged from 1990 to 2017. The largest study contained a 
sample of 7016 patients104 and the smallest study contained a sample of 13 patients.105 Methods 
utilized to collect data included observational cohorts (12%), retrospective chart review (4%), 
electronic medical records analyses (4%), prospective cohort (4%), retrospective cohort (4%), 
semi-structured and structured interviews (4%), case-controls (8%), cross-sectional studies (12%), 
and randomized trials (48%). Patients included in studies ranged from 18 to 95 years. Depending 
on the study design, the duration of included studies ranged from 4 weeks to 6 years. Among 
included studies, 9 (36%) were US-based. The review contained studies assessing multiple 
antidepressant medications, including milnacipran, fluoxetine, agomelatine, sertraline, citalopram, 
alprazolam, nortriptyline, bupropion, fludiazepam, and paroxetine and the comparison arms 
contained placebo, another antidepressant, interpersonal psychotherapy (IPT), cognitive 
behavioral therapy (CBT) or no treatment.  
 
A total of 14 studies (56.0%)85,106-118 indicated that antidepressant usage was associated with 
improvement in either FBG or HgA1c whilst 11 studies (44.0%)103-105,119-126 showed no association 
or non-statistically significant changes. Studies employed various tools to operationalize 
psychiatric outcomes, including the Patient Health Questionnaire (PHQ-2+, PHQ-9) (12%), 
Hamilton Depression rating scale (HAM-D) (28%),  Hospital Anxiety-Depression Scale (HADS) 
(28%),  the Montgomery-Äsberg Depression Rating Scale (MADRS) (8%), Short Form-36 (SF-
26 
36) (12%), Brief Disability Questionnaire (BDQ) (4%), Self-Care Inventory (4%), Mini Mental 
State Examination (4%), Beck Depression Inventory (BDI) (48%), SCL-90R anxiety score (4%), 
Hopkins Symptom Checklist (4%), Trait anxiety score (4%), State anxiety score (4%), RAND-36 
(4%), PAID sum score (4%), Edinburgh Postnatal Depression Screening tool (EPDS) (4%).
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Table 1: Details of studies identified in the systematic review 
Author 
(year) Objective 
Patient 
population Study design 
Outcomes of 
interest Results 
Abrahamian 
(2012)106 
To replicate earlier pilot 
study using a similar protocol 
(enlarging sample size to 
tackle the limitations in an 
earlier study) 
140 T2DM 
patients with co-
morbid depression. 
Mean age = 63 
years; M/F = 
45%/55% 
Observational 
cohort (open-label) 
study 
FBG, HgA1c 
Statistically significant improvements for FBG 
levels, HgA1c, body weight, blood pressure, BMI, 
total cholesterol, and serum triglycerides. 
Antidepressant responders and non-responders had 
significant and similar improvements in FBG and 
HgA1c. In contrast, responders had significantly 
greater reductions in body weight, BMI, total serum 
cholesterol, and triglycerides compared to non-
responders.  
Abrahamian 
(2009)107 
To evaluate the efficacy of 
long-term treatment with the 
antidepressant, milnacipran, 
in T2DM patients with co-
morbid depression by 
measuring in parallel effects 
on depressive symptoms and 
metabolic parameters. To 
evaluate the practicability of 
using a simple two-question 
screening tool for depression 
in the non-psychiatric setting 
of DM outpatient 
departments 
64 T2DM patients 
with co-morbid 
depression. Mean 
age = 61 years; 
M/F = 40%/60% 
Observational 
cohort 
FBG, HgA1c, 
BDI 
BDI scores improved over the duration of the study. 
After 1 month of treatment, 20.3% of patients had 
responded to antidepressant treatment, 51.6%, after 3 
months and 71.9% after 6 months. There was no 
difference between responders and non-responders 
concerning age, severity of depression, metabolic 
control or BMI at baseline. Mean dose of 
milnacipran administered during the final three 
months was significantly higher in responder 
patients than non-responder patients. FBG, HgA1c, 
BMI, serum total and LDL and triglyceride levels 
were all significantly decreased in antidepressant-
responder patients whereas in non-responders to 
antidepressant treatment these parameters were not 
significantly changed. 
Acee 
(2012)119 
To investigate whether 
identification and treatment 
of depression using current 
practice patterns improved 
management of DM as 
measured by A1c. To assess 
the effect of antidepressant 
medication management of 
participants with depression 
54 T2DM Hispanic 
patients. Mean age 
= 59.43 years; M/F 
= 25.9%/74.1% 
Non-experimental 
descriptive 
correlational study, 
interview surveys 
and retrospective 
chart review 
HgA1c, glucose 
self-monitoring, 
PHQ-9 
The logistic regression revealed that participants 
treated with an antidepressant were 3.4 times more 
likely to have HgA1c ≥8%. Additional analysis 
using repeated measures indicated that levels of 
depression and HgA1c levels are increasing 
simultaneously at alarming levels. In contrast, 
participants not treated with an antidepressant had 
equal odds ratios for HgA1c ≥8%. 
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(PHQ-9) on diabetic 
outcomes. 
Breum 
(1995)108 
To examine if fluoxetine 
improves glycemic regulation 
in obese diabetic patients 
40 obese patients 
with T2DM or 
impaired glucose 
tolerance. 20 
patients in 
fluoxetine group 
M/F = 35%/65%, 
mean age = 
43.6 ± 9.8 years; 
14 patients in 
placebo group M/F 
= 25%/75%, mean 
age = 44.3 ± 8.7 
years 
Randomized 
double-blind, 
placebo-controlled 
study 
FBG, HgA1c, 
OGGT, glucose 
tolerance, insulin 
levels 
Glycemic regulation improved significantly in both 
treatment groups. In the fluoxetine group, there was 
a tendency for a larger decline in HgA1c and insulin 
levels, but the difference only reached statistical 
significance for C-peptide levels at the 12-month 
visit. Fasting glucose levels declined significantly in 
the fluoxetine group during the study period, 
whereas levels were unchanged in the placebo group. 
The improvement in glucose tolerance also tended to 
be more pronounced in fluoxetine patients, but the 
differences were not significant. 
Brieler 
(2016)109 
To determine whether the use 
of ADM is associated with 
glycemic control in depressed 
patients with T2DM 
1399 T2DM 
patients. Mean age 
= 61.6 years; M/F 
= 41.2%/58.8% 
Retrospective 
cohort study 
(electronic medical 
records analysis; 
2009-2012) 
HgA1c, clinic 
utilization, 
insulin or other 
diabetic drug 
prescriptions, 
anxiety disorder 
Good glycemic control was achieved by 50.9% of 
depressed subjects receiving ADM versus 34.6% of 
depressed subjects without ADM. After adjusting for 
covariates, depressed patients receiving ADM were 
twice as likely as those not receiving ADM to 
achieve good glycemic control. 
Gehlawat 
(2013)110 
To examine the effect of 
escitalopram therapy on 
depressive symptoms and on 
glycemic control in patients 
with co-morbid depression 
and DM 
49 T2DM patients. 
Mean age = 50.75 
(±8.88) years; M/F 
= 25%/75% 
Semi-structured 
clinical interview 
HAM-D 
assessment at 3, 
6, and 12 weeks; 
fasting and post-
prandial BG, 
HgA1c 
A significant decline in mean HAM-D scores was 
observed 3 weeks onwards till the end of the study 
during escitalopram therapy. There was a 
corresponding decline in mean fasting and PPBG 
level at 6 and 12 weeks respectively and HgA1c at 
12 weeks was observed. 
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Gois 
(2014)120 
To investigate the 
improvement of major 
depression in a group of 
T2DM patients with a non-
pharmacological, well 
validated treatment (IPT) in 
non-diabetic populations, as 
against a pharmacologic 
treatment (sertraline), which 
has already been proved 
efficacious in patients with 
T2DM 
34 T2DM patients 
with depression. 
Mean age = 55.14 
years; M/F = 
11.8%/88.2% 
Randomized 
experimental, 
structured interview 
HgA1c, 
Psychological 
adjustment to 
DM, attachment 
style, DM self-
efficacy, quality 
of life, HADS, 
MADRS and a 
structured 
interview (Mini-
International 
Neuropsychiatric 
Interview) 
Out of 22 early-responding patients (11 for each 
treatment type), 16 had clinically significant 
improvements at endpoint with 11 reaching 
remission, and with no significant differences 
between IPT and sertraline. Within sequential add-
on treatment, out of eight patients, only three of 
them achieved a clinically significant improvement 
and only one reached remission. 
Gulseren 
(2005)121 
To investigate the efficacy of 
fluoxetine and paroxetine on 
the levels of depression–
anxiety, quality of life, 
disability, and metabolic 
control in T2DM patients 
20 T2DM patients 
(fluoxetine n=11, 
paroxetine 
n=9). M/F = 
17%/3% 
Randomized 
experiment 
HgA1c, HADS, 
interview, 
HARS, SF-36, 
BDQ 
Non-statistically significant improvement 
Karaiskos 
(2013)111 
To compare the efficacy of 
agomelatine and sertraline in 
the treatment of symptoms of 
depression/anxiety, DM self-
care and metabolic control in 
a sample of depressed 
patients with non-optimally 
controlled T2DM 
Agomelatine group 
(n=20): mean age 
= 54.3 years. 
M/F=NA; 
Sertraline group 
(n=20): mean age 
= 52.4 years M/F = 
NA 
Observational open-
label study 
HgA1c, FBG, 
HDRS, HARS; 
SCI-R, MMSE 
Lower anxiety and depression scores as well as 
higher self-care scores were measured in the 
agomelatine group compared with the sertraline 
group after 4 months of treatment. Although the 
main effects of treatment on final body weight and 
fasting plasma glucose were not significant, 
significantly lower final HgA1c levels were 
measured in the agomelatine group compared with 
the sertraline group. 
Khazaie 
(2011)112 
To compare the 
antidepressant effects of 
citalopram and fluoxetine in 
patients with comorbid 
depression and DM, and also 
the effect of these drugs on 
glycemic control and diabetic 
status 
40 patients. Mean 
age = 48.3 (±8.6) 
years; M/F = 
65%/35% 
(fluoxetine), M/F = 
55%/45% 
(citalopram) 
Randomized clinical 
trial 
HgA1c, 
FBS, BDI, 
interview 
After the 12-week treatment, both groups showed 
significant improvement in severity of depression, 
FBG, and HgA1c. 
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Lustman 
(2006)113 
To determine whether 
maintenance therapy with 
sertraline hydrochloride 
prevents recurrence of major 
depression in patients with 
DM 
152 patients, Mean 
age = 52.8 ± 12.3 
years; M/F= 
40.1%/59.9%. 
Patients on 
sertraline (n=79): 
mean age = 50.5 ± 
11.7 years; M/F= 
41.8%/58.2%; 
Patients on 
placebo: (n=73): 
mean age = 55.3 ± 
12.5 years; M/F = 
38.4%/61.6% 
Randomized, 
double-blind, 
placebo controlled, 
maintenance 
treatment trial 
HgA1c, length 
of time 
(measured as 
days after 
randomization) 
to recurrence of 
major 
depression, BDI; 
HAM-D, DM 
management 
HgA1c levels decreased during the open treatment 
phase and remained significantly lower than baseline 
during depression-free maintenance and did not 
differ between treatment groups. 
Lustman 
(2000)85 
To determine the 
antidepressant efficacy of 
fluoxetine in diabetic patients 
with major depressive 
disorder, to study the effects 
of treatment and depression 
improvement on glycemic 
control 
60 patients with 
DM (T1DM n=26; 
T2DM n=34). M/F 
= NA, Fluoxetine 
group: n=27, Mean 
age = 45 ± 13.0; 
Placebo group: 
n=27, Mean age = 
47.7 ± 11.5 
Randomized 
double-blind 
placebo-controlled 
trial 
HgA1c, 
BDI, HAM-D, 
insulin treatment
Reduction in depression symptoms was significantly 
greater in patients treated with fluoxetine compared 
with those receiving placebo. The percentage of 
patients achieving a significant improvement in 
depression per the BDI was also higher in the 
fluoxetine group. Additionally, trends toward a 
greater rate of depression remission and greater 
reduction in HgA1c were observed in the fluoxetine 
group. 
Lustman 
(1995)114 
To determine the effects of 
alprazolam on glucose 
regulation in anxious and 
non-anxious patients with 
poor glycemic control and 
establish whether regulatory 
benefits are related to 
anxiolytic effects of the 
medication 
58 patients (T1DM 
n=17; T2DM 
n=41). Alprazolam 
group n=21 mean 
age = 51.7 ± 13.1 
M/F = 67%/33%, 
placebo group 
n=37 mean age = 
50.2 ± 13.6, M/F = 
54%/46% 
Randomized, 
double-blind, 
placebo-controlled 
trial 
HgA1c, DM 
duration and 
complications, 
SCL-90R 
anxiety score, 
Hopkins 
Symptom 
Checklist 
A statistically significant reduction in glycated 
hemoglobin level was observed in patients treated 
with alprazolam compared with those receiving 
placebo. This treatment effect was not a function of 
differences in compliance behaviors. Anxiety 
symptoms decreased in both alprazolam- and 
placebo treated patients with generalized anxiety 
disorder, but reduction in glycated hemoglobin level 
was not dependent on alleviation of anxiety. The 
results of the ANCOVA showed that there were 
significant effects for the covariate and for the 
treatment group. Patients treated with alprazolam 
evidenced a significantly greater reduction in HgA1c 
level than those receiving placebo.  
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Lustman 
(1997)122 
To evaluate the effects of 
nortriptyline on depression 
and glycemic control to see 
whether depression in DM is 
treatable and whether 
restoring mental health 
contributes to improved 
medical outcome 
68 patients (T1DM 
n =23; T2DM 
n=45). 
Nortriptyline group 
n=26, mean age = 
49.2 ± 12.9 M/F = 
38.5%/61.5%, 
Placebo group 
n=42, mean age = 
49.0 ± 13.7 M/F = 
54.8%/45.2% 
Randomized, 
double-blind 
placebo-controlled 
trial 
HgA1c, BDI, 
treatment 
regimen, compli
ance with 
SMBG and 
treatment 
Nortriptyline was not statistically superior to placebo 
in reducing HgA1c of the depressed subjects. 
However, path analysis indicated that the direct 
effect of nortriptyline was to worsen glycemic 
control whereas depression improvement had an 
independent beneficial effect on HgA1c. These 
findings were not explained by the relationships of 
nortriptyline treatment to weight change or 
depression improvement to compliance with the 
protocol for self-monitoring of BG. 
Lustman 
(2007)115 
To use bupropion 
hydrochloride to determine 
whether this improvement 
could be attributed to 
changes in anthropometrics 
or DM self-care 
93 T2DM patients 
with and major 
depressive 
disorder. Mean age 
= 51 years; M/F = 
36%/64% 
Two-phase, open 
label treatment trial 
HgA1c, BMI, 
BDI  
BMI, total fat mass, and HgA1c decreased and 
composite DM self-care improved over the acute 
phase, effects that persisted through the maintenance 
phase for BMI, HgA1c, and self-care. Reductions in 
BMI and depression severity independently 
predicted lower HgA1c after acute-phase treatment, 
whereas only reduction in depression severity 
predicted HgA1c over the maintenance interval. 
Marrero 
(2015)116 
To examine changes in 
depressive symptoms and 
ADM use immediately after 
diagnosis of DM in the DPP 
cohort. To examine 
relationships between 
depressive symptoms, ADM 
use, and glycemic control 
(HgA1c, FBG) in the DPPOS 
study cohort at follow-up 
assessment time points after 
DM diagnosis 
Among 3234 
participants, 1285 
developed 
DM. Mean age = 
49.4 years; M/F = 
32%/68% 
Observational 
cohort 
HgA1c, FBG, 
quality of 
glucose control, 
BDI, and the use 
of anti-
depression 
medications 
Among 3234 participants, 1285 developed DM. 
Depression levels were measured before and after 
DM diagnosis. Higher FBG was associated with 
greater ADM use in the intensive lifestyle arm; a 10-
mg/dl rise in FBG is associated with greater odds of 
ADM use. There was a significant treatment 
interaction with two predictors, FBG (p=0.01) and 
HgA1c (p=0.01). This finding demonstrates a 
positive relationship between depressive symptoms 
and FBG and HgA1c 
Mast 
(2017)104 
To assess the prevalence of 
antidepressants, anxiolytics, 
and/or hypnotics use in a 
large, managed, primary care 
system cohort of people with 
T2DM and to determine the 
7016 patients with 
T2DM. Mean age= 
66.3 (±11.7); M/F 
= 52.2%/47.8% 
Prospective cohort 
(2007-2012) 
HgA1c, 
medications, 
comorbidities, so
ciodemographic 
patterns 
From the 7016 people with T2DM, 17% of all 
people with T2DM used antidepressants, anxiolytics, 
and/or hypnotics. Users were more often female, 
non-Caucasian, lower educated, and more often 
treated with insulin. Finally, compared to nonusers, 
those people using antidepressants more often used 
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sociodemographic 
characteristics, comorbidities, 
T2DM medication, and 
metabolic control associated 
with its use 
insulin as T2DM treatment. No differences were 
observed in T2DM treatment between nonusers and 
anxiolytics and/or hypnotics users. Additionally, no 
significant differences were observed in continuous 
HgA1c or cut-off variables for HgA1c levels (≥53 
mmol/mol) between users and nonusers. 
Okada 
(1995)117 
To assess using State-Trait 
Anxiety Inventory scores in 
40 T2DM patients, and the 
results were compared with 
those for 40 sex- and age-
matched healthy controls. To 
assess fludiazepam 
administered to the patients 
for 12 weeks and stress  
40 cases, mean age 
= 62.0 (±12.7); 
M/F = 55%/45%. 
40 controls, mean 
age = 59.5 (±13.7); 
M/F = 50%/50% 
Case-control 
HgA1c, Trait 
anxiety score, 
State anxiety 
score 
Administration of an anxiolytic, fludiazepam 
lowered Trait score, State score, HgA1c, systolic 
blood pressure and diastolic blood pressure. Multiple 
regression analysis revealed that the significant 
explanatory variables for the change in State score 
during anxiolytic administration were the changes in 
total cholesterol, high-density lipoprotein 
cholesterol, triglycerides, apolipoprotein B:A1 and 
HgA1c. 
Paile-
Hyvärinen 
(2003)105 
To evaluate the effect of the 
antidepressant paroxetine on 
metabolic control, quality of 
life and mental well-being in 
mildly depressed women 
with T2DM 
Paroxetine group: 
n=7, mean age = 
61.1 years, M/F = 
NA. controls 
group: n=6, mean 
age = 62.3 years 
Randomized, single-
blind, placebo 
controlled trial 
HgA1c, Blood 
glucose, BDI, 
HAM-D, 
MADRS, RAND
-36, energy 
expenditure 
A trend towards a superior improvement in glycemic 
control was found in the paroxetine group. A 
superior increase in SHBG levels was evidenced in 
the paroxetine group as a sign of improved insulin 
sensitivity. There was also a trend for superior 
efficacy of paroxetine in investigator-rated anxiety 
and depression. This notion was supported by a trend 
for superior decrease of serum cortisol levels in the 
paroxetine group. 
Paile-
Hyvarinen 
(2007)123 
To evaluate the effect of the 
antidepressant paroxetine on 
quality of life, metabolic 
control, and mental well-
being in mildly depressed 
diabetics aged 50–70 years 
23 paroxetine. 
Mean age = 59.2 
years, M/F 
= 74%/26%. 20 
controls. Mean age 
= 59.5 years, 
M/F=80%/20%. 
Randomized 
double-blind, 
placebo-controlled 
study 
HgA1c, BMI, 
Fasting serum 
glucose, HADS, 
SF-36 
After three months of treatment we found a 
statistically significant difference between the two 
treatment groups in HgA1c and in SF-36 score. 
However, at the end of the study, no statistically 
significant differences between the treatment groups 
were observed. No severe adverse events occurred. 
Petrak 
(2015)124 
To compare the long-term 
efficacy of a DM-specific 
cognitive behavioral 
 group therapy (CBT) with 
sertraline in patients with 
DM and depression 
61 patients with 
T2DM in CBT 
group: mean age = 
49.0 years; M/F = 
37.3%/62.7%. 61 
patients with 
Randomized, single-
blind controlled trial
HgA1c, HAMD-
17 scores, PAID 
sum score, SF-
36 HRQoL, 
Remission of 
depression 
After 12 weeks, 45.8% of patients responded to 
antidepressant treatment and were included in the 1-
year study phase. Adjusted HgA1c mean score 
changes from baseline to the end of the long-term 
phase revealed no significant difference between 
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 who initially responded to 
short-term depression 
treatment 
T2DM in sertraline 
group: mean age = 
47.9 years; M/F = 
38.4%/61.6%. 
interventions. Depression improved in both groups, 
with a significant advantage for sertraline. 
Qu 
(2005)118 
To investigate the influence 
of improving depression and 
anxiety on metabolism of 
blood glucose 
43 patients with 
T2DM (n=23 
cases, n=20 
controls).  Mean 
age = 51 (±9) 
years; M/F 
= 55.8%/44.2% 
Randomized, 
controlled 
comparative study 
HgA1c, FBG, 
preprandial 
blood glucose 
level and 1-hour 
preprandial 
blood glucose 
level 
After 4 weeks the FBG and 2-hour post prandial in 
experimental group were significantly lower than 
those in control group. 
Schierhout 
(2013)125 
To report on evidence-
practice gaps, and compare 
differences in depression 
screening, documentation and 
management between 
patients with different levels 
of disease severity, co-
morbidity and DM control 
1174 patients with 
T2DM. M/F 
= 41.66%/58.34%, 
median age = 51.5 
years (age groups 
are reported) 
Observational study, 
cross-sectional 
HgA1c, BMI, 
Diabetes 
treatment, K-
5/10, PHQ-2+, 
PHQ-9, EPDS 
Patients with poorer cardio-metabolic control and 
greater disease severity were less likely to have 
attention paid to potential co-morbid depression. 
Screening for depression was lower for those on 
pharmaceutical treatment for glycemic control 
compared to those not on such treatment. 
Antidepressant prescription was not associated with 
level of DM control or disease severity. 
Rim Song 
(2014)126 
To evaluate the positive and 
negative effects of 
mirtazapine in diabetic 
patients undergoing 
naturalistic treatment 
33 patients with 
DM in mirtazapine 
group: mean age = 
59.1 (±10.2) 
years, M/F = 
39.4%/60.6%. 33 
patients in control 
group: mean age = 
60.0 (±10.0) 
years; M/F = 
39.4%/60.6%. 
Case-control study 
HgA1c, FBG, 
diabetes 
treatment, dose 
of mirtazapine, 
duration of 
depressive 
symptoms, 
previous 
depressive 
episodes 
The two groups did not differ in any baseline 
characteristics except for total cholesterol levels. 
Body mass index increased in both groups, and the 
change in the mirtazapine group was significantly 
greater than that in the control group at 6 months. 
Only the control group exhibited a decrease in 
fasting plasma glucose, whereas both groups showed 
a decrease in HgA1c, low-density lipoprotein, and 
total cholesterol, an increase in high-density 
lipoprotein, and no change in triglyceride levels. 
None of the differences between the groups were 
statistically significant. 
Yekta 
(2015)103 
To determine if the use of 
antidepressants was 
associated with lower odds of 
diabetic retinopathy and if so, 
to determine if this 
1041 T2DM 
patients taking 
antidepressant 
therapy (n=186) vs 
none (n=958). Age 
Cross-sectional 
study 
HgA1c, Insulin 
medication, type 
and duration of 
antidepressant 
medication, 
Duration of DM, HgA1c, serum triglycerides, 
systolic blood pressure, and income were not 
significantly different between participants taking 
antidepressants compared to those not taking 
antidepressants. 
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association was mediated by 
decreased inflammation as 
measured by CRP 
40–85 years, M/F 
= 48.4%/ 51.6% 
Ratio of family 
income to the 
federal poverty 
level 
 
ADM = antidepressant medication; ANCOVA = analysis of covariance; BDI = Beck Depression Inventory; BDQ = Brief Disability 
Questionnaire; BMI = body mass index; CBT = cognitive behavioral group therapy; CRP = C-reactive protein; DM = diabetes 
mellitus; EPDS = Edinburgh Postnatal Depression Screening; FBG = fasting blood glucose; HADS = Hospital Anxiety-Depression 
Scale; HAM-D = Hamilton Depression rating scale; HARS = Hamilton Anxiety Rating Scale; HgA1c = glycosylated hemoglobin; K-
5/10 = Kessler Psychological Distress Scale; IPT = intrapersonal psychotherapy; LDL = low density lipoprotein; MADRS = 
Montgomery-Äsberg Depression Rating Scale; MMSE = Mini Mental State Examination; M/F = male/female; OGGT = oral glucose 
tolerance test; PAID = Problem Areas in Diabetes Questionnaire; PHQ-9 = Patient Health Questionnaire-9; PPBG = post-prandial 
blood glucose; SCI-R = Self-Care Inventory, Revised; SCL-90R = Symptom Checklist-90 Revised; SF-36 = Short-Form-36; SHBG = 
sex-hormone-binding-globuline; SMBG = self-monitoring of blood glucose; T2DM = type 2 diabetes mellitus 
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b. Specific studies 
As stated previously, more than half of studies indicated that receiving antidepressants resulted in 
improved glycemic profiles in patients with T2DM. In a pilot study in 2009,107 Abrahimian et al 
found that treatment with the SNRI milnacipran significantly improved metabolic parameters in 
patients with T2DM and comorbid depression who had an antidepressant response. In fact, 
Hemoglobin A1c, fasting blood glucose, body mass index, total and LDL-cholesterol and serum 
triglyceride levels were all significantly decreased in patients with antidepressant response at the 
end of the study whereas in antidepressant non-responders these parameters were not significantly 
changed. Replicating these findings to a larger cohort in 2012,106 72.6% of patients had an 
antidepressant response (defined as ≥50% reduction of baseline BDI score) and the number of 
patients with poor HgA1c decreased during the study. In contrast to the pilot study, FBG and 
HgA1c were significantly decreased to a similar extent in both antidepressant-responders and non-
responders. 
 
In another retrospective cohort study109 of a large sample of primary care patients with T2DM, 
antidepressant use was associated with improved glycemic control. Indeed, good glycemic control 
was achieved by 50.9% of depressed subjects receiving antidepressants versus 34.6% of depressed 
subjects without antidepressants. After adjusting for covariates, depressed patients receiving 
antidepressants were twice as likely as those not receiving antidepressants to achieve good 
glycemic control (odds ratio [OR]: 1.95; 95% confidence interval: 1.02–3.71). The antidepressants 
included TCAs (clomipramine, amitriptyline, desipramine, nortriptyline, doxepin and 
imipramine); SSRIs (citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine and 
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sertraline); SNRIs (venlafaxine, duloxetine and desvenlafaxine); and non-classified 
antidepressants (bupropion, nefazodone, trazodone and mirtazapine). The other 12-week study on 
the effect of escitalopram110 in patients with T2DM reported corresponding decline in mean fasting 
and post-prandial BG at 6 and 12 weeks respectively and HgA1c level at 12 weeks. 
 
In an observational open label study,111 depressed patients with non-optimally controlled T2DM 
were randomly assigned to agomelatine group or sertraline group. As a result, though the main 
effects of treatment on final body weight and FBG were not significant, significantly lower final 
HgA1c levels were measured in the agomelatine group compared with the sertraline group. Thus, 
this study is considered to be an evidence for positive influence of an antidepressant (agomelatine) 
on HgA1c. 
 
Two case-controls were included in current systematic review. The first case-control was 
conducted in Japan to evaluate effects of fludiazepam on T2DM patients117 showed significant 
improvements in both anxiety scores and HgA1c at the end of the study period.  
 
The only study114 in this systematic review conducted on patients with anxiety sought to determine 
the effects of alprazolam on glucose regulation. The research found a statistically significant 
reduction in HgA1c was observed in patients treated with alprazolam compared with those 
receiving placebo (-1.1 vs. -0.3%, p=0.04).  
 
As stated earlier, in this systematic review, randomized trials composed the majority of study 
designs. In a randomized control trial,112 patients with T2DM and comorbid depression were 
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randomly assigned fluoxetine or citalopram. After the 12-week treatment, both groups showed 
significant improvement in FBG and HgA1c. There were no significant differences between the 
two groups in terms of improvement in diabetic status. A few years later, a similar study127 
randomly assigned patients with DM to either fluoxetine or placebo and indicated that greater 
reduction in HgA1c (-0.40% vs. -0.07%; p=0.13) were observed in the fluoxetine group. The other 
similar study115 in this group was a two-phase, open label treatment trial on patients with T2DM 
and MDD received bupropion. As a result, BMI, total fat mass, and HgA1c decreased and 
composite DM self-care improved over the acute phase (-0.5 kg/m2, -0.7 kg, -0.5%, and +0.4, 
respectively, p<0.01 for each), effects that persisted through the maintenance phase for BMI, A1C, 
and self-care (p<0.01 for each). In another 12-month, randomized, placebo-controlled study,108 
fluoxetine was compared to placebo. Both groups showed a significant weight loss, however 
glycemic regulation improved along with the weight loss, but with a larger decline in plasma C-
peptide and FBG levels in the fluoxetine group (p<0.05). In this group compared to placebo group, 
there was a tendency for a larger decline in HgA1c but it did not reach the statistical significance. 
Another randomized controlled comparative study in China compared routine treatment of 
diabetes with receiving paroxetine and alprazolam.118 For experimental group, besides routine 
medications for diabetes, patients also received anti-depression and anti-anxiety treatment, 
including paroxetine (20 mg, once every day) and alprazolam (0.4 mg, twice every day). For 
control group, patients only received routine medication for diabetes. After four weeks, the FBG 
and 2-hour post prandial BG in experimental group were significantly lower than those in control 
group. After 4 weeks medication, the post-treatment HgA1c level in experimental group were 
significantly lower than pre-treatment HgA1c level (p<0.05). 
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On the other hand, a number of studies failed to statistically prove any improvement in glycemic 
outcomes. Of note, none made it to statistically prove any exacerbation in the entire patient 
population. Findings of a study conducted in a Hispanic population119 revealed that participants 
treated with an antidepressant were 3.4 times more likely to have HgA1c levels of ≥8% (p=0.11). 
Due to the small sample size (n=11), this trend is needed to be replicated in bigger populations. 
 
In an observational study,116 diabetes prevention program participants were assessed in three 
treatment arms including (1) intensive lifestyle, (2) metformin, (3) placebo for glucose control, 
antidepressant medication use, and depressive symptoms using BDI. Among 3234 participants, 
1285 (40%) developed diabetes. Interestingly, higher FBG and HgA1c were associated with higher 
BDI scores in all three arms, with a 10-mg/dl rise in FBG lending a 0.07-point increase in BDI, 
and a 1% increase in HgA1c associated with a 0.21-point increase in BDI. In addition, the 
relationship between FBG and HgA1c and the likelihood of taking antidepressants was not 
significant in metformin group and placebo group. Nevertheless, higher FBG levels were 
associated with greater antidepressant use only in the intensive lifestyle group (OR: 1.088; 95% 
CI: 1.044–1.135, p<0.0001). The other observational study was cross-sectional research on 
patients with T2DM from multiple centers in Australia.125 HgA1c goal attainment was not 
statistically different among depression screened patients, documented depression patients and 
those with antidepressant prescriptions.  
 
A cross-sectional study conducted on National Health and Nutrition Examination Survey 
(NHANES) database in the US103 sought to evaluate whether use of antidepressants was associated 
with lower odds of diabetic retinopathy or not. Evaluating T2DM patients taking antidepressant 
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versus not taking antidepressant, the research indicated that duration of diabetes and HbA1c were 
not significantly different between participants taking antidepressants compared to those not taking 
antidepressants. 
 
The second case control included in current review126 sought to assess any effect that treatment 
with mirtazapine may incur in diabetic patients in Korea. This study included 33 diabetic patients 
with depression who had been prescribed mirtazapine for at least 6 months and 33 diabetic patients 
who had not taken any psychiatric medicines as a control group. Outcomes including FBG, HgA1c 
were assessed at baseline, 3 months, and 6 months. As a result, HgA1c demonstrated a linear 
decrease in both the control and mirtazapine groups. FBG decreased linearly in the control group, 
but there was no significant difference in the changes between the two groups. In fact, the decreases 
in FBG (p=0.098) and HgA1c (p=0.11) were not significant between the two groups at 6 months. 
 
The next study was a cohort on people with T2DM to assess the prevalence of antidepressants, 
anxiolytics, and/or hypnotics use and determine metabolic control associated with it.104 The unique 
feature of this study was reporting separately the prevalence of antidepressants, 
anxiolytics/hypnotics and combination use of antidepressants and anxiolytics/hypnotics in three 
groups. No significant differences were observed in continuous HgA1c or cut-off variables for 
HgA1 levels between users and nonusers. In a 6-month randomized study,120 T2DM patients were 
randomized to undergo interpersonal psychotherapy (IPT) or treatment with sertraline. After three 
months, HgA1c measured in patients receiving sertraline were not significantly different from 
those under IPT (p=0.781). In another similar experiment,121 patients with T2DM were randomized 
to receive fluoxetine or paroxetine for 12 weeks. At the end of treatment, a decrease was observed 
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in HgA1c values of the fluoxetine-administered group however the decrease was not statistically 
significant.   
 
The other study113 was conducted on T2DM patients who recovered from depression. During this 
open-label randomized, double-blind, placebo controlled, maintenance treatment trial assigned 
patients to receive sertraline or placebo (n=73) for up to 52 weeks or until depression recurred. 
HgA1c levels decreased during the open treatment phase (p=0.002) but did not differ between 
treatment groups (p=0.90). The other similar study122 in this group a randomized, was placebo-
controlled, double-blind trial involving eight weeks of treatment with nortriptyline. Nortriptyline 
was not statistically superior to placebo in reducing HgA1c of the depressed subjects (P = 0.5).  
 
Two randomized trials conducted in Finland by Paile-Hyvarinen et al105,123 faced an initial 
improvement but failed to conclude a statistically significant improvement in glycemic outcomes 
by the end of study. The first one on 2003 was a single-blind randomized placebo-controlled trial 
to evaluate the effect of paroxetine on metabolic control in mildly depressed women with T2DM. 
A trend towards a superior improvement in glycemic control was found in the paroxetine group 
but the change was statistically insignificance (p=0.08). After this small-scale pilot study, a 
double-blind randomized placebo controlled 6-month trial was carried out in 2007 to evaluate the 
effect of paroxetine on metabolic control in mildly depressed patients with DM aged 50–70 years. 
After three months of treatment a statistically significant difference between the two treatment 
groups was found in HgA1c (mean difference = 0.59%, p=0.018). However, at the end of the study, 
no statistically significant differences between the treatment groups were observed.  
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Moreover, a randomized controlled single-blind multicenter trial compared the long-term efficacy 
of a diabetes-specific cognitive behavioral group therapy (CBT) with sertraline in patients with 
diabetes and depression across Germany.124 After 12 weeks, treatment responders (≥50% reduction 
Hamilton Depression Rating Scale [HAMD-17]) were included in the one-year study phase where 
CBT patients were encouraged to use bibliotherapy and sertraline patients received continuous 
treatment. Adjusted HgA1c mean score changes from baseline to the end of the long-term phase 
(change: -0.27; 95% CI (-0.62- 0.08)) revealed no significant difference between interventions. 
Depression improved in both groups, with a significant advantage for sertraline (p<0.05). 
V. Discussion 
According to the evidence gathered by the systematic literature review, previous literature 
indicates that antidepressant usage is mostly associated with better outcomes for T2DM. Although 
some of the included studies failed to identify a significant improvement in diabetic outcomes, 
majority of the studies observed improvement in diabetic outcomes among patients who had taken 
antidepressants. Indeed, no study in the review observed significant exacerbation in diabetic 
outcomes associated with antidepressant usage. 
a. Limitations 
At a review level, there were limitations that require addressing. As in most reviews, the quality 
of studies varied. The studies included various sample sizes and different patient populations, 
therefore making it more difficult to compare outcomes study to study, particularly from a 
quantitative perspective. The sample size in a few studies was too small to potentially lead to any 
solid conclusions. In addition, potentially significant factors such as medication adherence, along 
with severity of diabetes, were not considered. Also, some studies did not make it to the qualitative 
 42 
search because the type of diabetes was not clear (T1DM vs T2DM). Although the outcomes being 
compared were limited to main diabetic outcomes, not all studies were consistent in outcome of 
interest (eg, not all studies included both HgA1c and FBG). Lastly, there were variations in the 
type of antidepressants addressed from study to study, with SSRIs the most common class studied.  
 
At the researcher level, multiple limitations could affect the review’s results. First, the fact that 
only one investigator oversaw identifying, collecting, and assessing the data from previous 
literature might cause researcher bias. Moreover, including only English studies presents a bias, 
with articles written in other languages containing relevant data having been left out of the review. 
VI. Conclusion 
Overall, the literature shows that with antidepressants being increasingly prescribed in patients 
with T2DM, it is important to understand their impact on clinical outcomes, potentially influencing 
treatment decisions in diabetes care. The literature review indicates a paucity of research with 
larger sample size and various antidepressants. The logical next step for future research would be 
to observe clinical outcomes of diabetes, specifically HgA1c and FBG, and assess the influence of 
antidepressant usage upon them. Further data could help interventions tailor treatment to patients 
more effectively, help overcome barriers to treatment, and improve overall health outcomes. 
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CHAPTER THREE – METHODOLOGY 
 
The purpose of this study was four-fold: (1) to describe the prevalence of depression and anxiety 
in patients with T2DM, (2) to identify the factors associated with clinical outcomes of T2DM in 
patients with or without depression and/or anxiety, (3) to assess the influence of the severity of 
comorbid depression/anxiety diagnosis upon clinical outcomes for T2DM, and (4) to analyze 
potential predictors of treatment success for patients with T2DM.  
I. Study design 
This is a retrospective cohort study and utilized electronic medical record (EMR) data from a 
primary care physician (PCP) group practice based in Southwestern Pennsylvania. The EMR study 
utilized longitudinal data from 2004-2010, with patients evaluated across their first year post-
T2DM diagnosis. This study was approved by Duquesne University Institutional Review Board. 
a. Electronic Medical Records (EMR) 
EMR generally refers to standardized electronic databases for healthcare, which are developed, 
maintained, and/or provided by clinicians and providers in direct patient care. An EMR system 
contains information on all clinical, administrative, and laboratory encounters between a patient 
and provider.128,129  Currently, EMR systems are available at most large, integrated healthcare 
providers in the USA, such as Kaiser Permanente, Harvard Pilgrim Health System, and the 
Department of Veterans Affairs (VA).  
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EMR systems have the potential to provide clinical data required for research and with 
technological advancement, it has become a valuable source for outcomes research.  They offer 
various potential benefits in research by providing access to a fully integrated system with both 
clinical and healthcare utilization data. In addition, they provide access to readily available, in-
depth, more accurate, and complete data compared to traditional paper charting.130 
II. Data source 
Data was obtained from the GE Centricity Electronic Medical Records EMR database from the 
Preferred Primary Care Physicians (PPCP) group. The database contains more than 75,000 active 
patients receiving care from primary care providers in Southwestern Pennsylvania across a multi-
year period. Access to this data was enabled through an academic partnership agreement with the 
Duquesne University School of Pharmacy and the PPCP group; a copy of the data is hosted on a 
Duquesne University virtual server, with protected access.  
a. Database organization 
The EMR database is exported and provided in a structured query language (SQL) frame.  A 
database is a collection of tables which contain related information, and a table in a relational 
database is organized in rows and columns. Columns, also known as fields, represents a specific 
type of data stored in the table. For example, the demographic table includes columns such as 
patient ID, gender, race, marital status, etc. Each row, also known as records, represents a set of 
related data about a single object.  For example, each row in demographic table represents 
demographic information for each patient. Conversely, in medications table, each patient can have 
multiple prescriptions, so each row contains information for one specific prescribed medication.   
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b. Data extraction 
The data is accessed via Microsoft SQL Management Studio (Redmond, WA).  The data files exist 
as tables containing information for patient demographics, clinical diagnoses, prescribed 
medications, visits, and laboratory test results. Specific tables and columns were identified and 
linked using a unique patient ID (PID).  The related information in one table column was linked 
to information in another table column using PID as the primary key.  PID is a unique identification 
for each person or contact in the demographic table.  The PID is used in all the tables and is used 
to identify the information related to a specific person.  Selection criteria were used to extract only 
the required information for patients with T2DM. For statistical analyses, data from SQL were 
imported into Microsoft Excel (Redmond, WA) and/or IBM SPSS Statistics 24 (Armonk, NY). 
III. Location 
The greater Pittsburgh area is in the Northeastern region in the USA, with a population of 
the Pittsburgh metropolitan area around 2.35 million residents based on the 2014 data from the US 
Census Bureau. The median age of population is 43.1 years, and 51% are female. A total of 86% 
and 8% of population are Caucasian and African American, respectively.131 
 
IV. Study population 
Inclusion criteria for the study population included predominantly adult patients ≥18 years of age 
with a diagnosis of T2DM ascertained via International Classification of Disease – 9th edition 
Clinical Modification (ICD-9-CM) coding for 250.00 or 250.02. In order to determine the first 
appearance of coding for T2DM (i.e. initial diagnosis), patients must have had at least 6 months 
EMR data prior to diagnosis without coding for T2DM, and at least 12 months of EMR data after 
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the first code for T2DM. Therefore, all T2DM in this study were incident cases. Additionally, they 
had to have at least one visit with coding for T2DM post-first coding. Accordingly, coding meeting 
this criterion was considered the initial diagnosis of T2DM and the index date for the study. 
Patients with evidence of pregnancy were excluded from the study.  
V. Study variables 
a. Patient-related variables 
i. Age, gender, employment, race/ethnicity  
In this study, age was captured from the database at the index date. It was derived from data 
regarding the year of birth provided by the patient in the EMR, subtracted from the year of the 
index date to calculate participants’ ages. Data regarding gender was also captured, denoted as 
either male (‘M’) or female (‘F’) in the database. Data regarding employment status was available 
in the databases; however, due to the high level of missing data, it was not included in the analysis. 
Finally, race/ethnicity in the database was coded as: (1) Caucasian, (2) African American/Black; 
(3) Asian; (4) Hispanic; or (5) Other. Due to predominance of Caucasian race in the region, 
race/ethnicity was then recoded by the researcher as (1) Caucasian and (2) Other (Asian, African-
American, Hispanic, or Other).  
ii. Smoking status  
Data regarding smoking status was free-texted into the database by clinicians and recoded by the 
researcher into three categories: (1) Former smoker; (2) Never smoker; and (3) Current smoker. 
For the purposes of analysis, smoking status was ascertained for the year post-index, which 
included these three categories, as well as a status of “Changing”, which indicated one or more 
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change in their smoking status during the yearlong time frame. For example, a changing case 
would be a patient who changed the smoking status from current smoker to former smoker within 
the timespan. To reduce the level of missing data in the smoking variable, if smoking status was 
not available in the EMR post-index date, the closest prior smoking status available to the index 
rate was recorded as smoking status. 
iii. Height/weight at index 
Height and weight were extracted at the clinic visit at the time of index date. To reduce the level 
of missing data in the height/weight variables, if the measurement was not available at that visit, 
the closest available data prior to the index date was included. While height and weight were 
recorded in inches (in) and pounds (lb) respectively, the units were converted to meters (m) and 
kilograms (kg) for the purpose of calculating body mass index (BMI).   
iv. BMI at index 
BMI (kg/m2), defined as where kg is a person's weight in kilograms, and m2 is their height in 
meters squared, was calculated using weight and height data and was only available for patients 
who had both values available in the database. For adults, BMI is interpreted using standard weight 
status categories which are the same for men and women. According to CDC, BMI <18.5 is 
considered underweight, BMI from 18.5 to 24.9 is considered normal/healthy weight, BMI from 
25.0 to 29.9 and BMI ≥30 are defined as overweight and obese, respectively.  
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v. Marital status  
Marital status was reported in the database as (1) Single; (2) Divorced; (3) Married; and (4) 
Widowed. This variable was recoded by the researcher into two categories: (1) Married/domestic 
partner; and (2) Not married: single, divorced, and widowed. However, the variable was not finally 
included in the analysis due to a high level of missing data. 
vi. Selected comorbidities 
Selected medical comorbidities for query were chosen based on relative importance and 
prevalence in T2DM, based on published literature. They were identified by ICD-9-CM, including: 
(1) hypertension (ICD=401); (2) hypercholesterolemia (ICD=272); (3) neuropathy (ICD=50.6); 
(4) retinopathy (ICD=250.5); (5) chronic kidney disease (ICD=585); (6) heart failure (ICD=428); 
and (7) heart disease (ICD=410-414). The presence of these comorbidities was determined through 
appearance of their ICD-9 codes in the year post-index. 
vii. Total medications per patient 
The average number of unique medications (determined via distinct generic names) that each 
patient received in the first-year post-index was determined. This was utilized as a surrogate 
measure for complexity of illness. 
viii. Depression diagnosis 
The comorbid presence of depression was identified via ICD-9-CM = 311.xx and was recorded 
into two categories: (1) Before (or on) diabetes diagnosis, for patients where first depression 
coding occurred prior to or on the index date; and (2) After diabetes diagnosis, for patients where 
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depression coding first appeared after the index date. This was ascertained by identifying the 
earliest date of depression coding for a patient in the database and comparing it to the index date 
(T2DM diagnosis). 
ix. Anxiety diagnosis 
The comorbid presence of anxiety was identified via ICD-9-CM = 300.xx and was recorded into 
two categories: (1) Before (or on) diabetes diagnosis; and (2) After diabetes diagnosis, based on 
the same criteria discussed previously for depression.  
x. Diabetes treatment at index 
This was identified as the class of anti-diabetic treatment which patients were prescribed within 
60 days post-index. Medications were categorized by the researcher into: (1) Metformin; (2) 
Metformin and other oral agents; (3) Insulin only; (4) Oral agent(s) and insulin; and (5) Other. The 
list of anti-diabetic medications searched in the database includes: metformin, sulfonylureas 
(glimepiride, glipizide, glyburide, chlorpropamide, tolbutamide), sulfonylurea/metformin 
combinations, thiazolidinediones (pioglitazone, rosiglitazone), acarbose, miglitol, 
meglitinides (nateglinide, repaglinide), GLP-1 agonsts (liraglutide, exenatide), DPP-4 inhibitors 
(saxagliptin, sitagliptin) and insulins (Humulin, Novolin, Humalog, Novolog, Apidra, Semilente, 
regular, lispro, aspart, glulisine, isophane, neutral protamine Hagedorn [NPH], lente, ultralente, 
glargine, Lantus, Levemir and determir).  
xi. Number of anti-diabetic medications in first year post-diagnosis 
This variable was calculated as total number of above mentioned distinct anti-diabetic medications 
that each patient received in the first year following T2DM diagnosis. It was categorized to (1) 1 
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medication; (2) 2-3 medications; and (3) ≥ 4 medications. This was utilized as a surrogate measure 
for variability of T2DM regimen. For instance, a patient with more medications used in the first 
year post-diagnosis may have had their regiment augmented or switched, indicating a greater 
degree of variability in their treatment.  
xii. Number of office visits per patient in first year post-diagnosis 
This variable was calculated as the average number of office visits each patient had in the year 
following T2DM diagnosis. This was utilized as a surrogate measure for healthcare utilization. 
xiii. HgA1c at baseline 
This variable was identified by isolating the first HgA1c value each patient had post-index. Free-
texted non-numeric values such as “pending” or “gave rx” were identified by spot checking 
records, and were considered missing data. This variable was reported in three categories: (1) <7%; 
(2) 7-9%; and (3) >9%. 
xiv. Depression/anxiety treatment at index 
This was identified as the class of antidepressant/anti-anxiety treatment which patients were 
prescribed within 60 days post-index. The medications were put by the researcher into categories, 
including: (1) SSRI or SNRI only; (2) TCA only; (3) Benzodiazepine only; (4) Benzodiazepine + 
SSRI/SNRI; and (5) Benzodiazepine + TCA. The list of antidepressant/anti-anxiety medications 
searched in the database includes: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, paroxetine CR, sertraline), SNRIs (desvenlafaxine, duloxetine, levomilnacipran, 
milnacipran, venlafaxine, venlafaxine XR), bupropion (regular, SR and XL), mirtazapine, 
nefazodone, trazodone (regular and ER), vilazodone, vortioxetine, buspirone, TCAs 
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(amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, 
nortriptyline, protriptyline, trimipramine), MAOIs (isocarboxazid, phenelzine, selegiline, 
tranylcypromine), pregabalin, gabapentin, quetiapine, hydroxyzine, and benzodiazepines 
(alprazolam [regular and XR], bromazepam, chlordiazepoxide, clonazepam, clorazepate, 
diazepam, lorazepam, oxazepam, prazepam). 
xv. Number of antidepressant/anti-anxiety medications in first year post-diagnosis 
This variable was calculated as total number of above mentioned distinct antidepressant/anti-
anxiety medications that each patient received in the first year following T2DM diagnosis. It was 
categorized to (1) 1 medication, (2) 2-3 medications, and (3) ≥4 medications. This was utilized as 
a surrogate measure for variability of depression/anxiety regimen. 
xvi. Cholesterol medications in first year post-diagnosis 
This variable was identified by determining the presence of cholesterol treatment (Yes/No) in the 
year post-index. The list of medications searched in the database included: statins (lovastatin, 
pravastatin, simvastatin, atorvastatin, rosuvastatin), bile acid sequestrants (cholestyramine, 
colestipol, colesevelam), fibrates (gemfibrozil, fenofibrate, clofibrate), ezetimibe, alirocumab, 
evolocumab, mipomersen, lomitapide, niacin, fluvastatin, pitavastatin, and omega-3 fatty acids.  
xvii. Blood pressure medications in first year post-diagnosis 
This variable was identified by determining the presence of blood pressure treatment (Yes/No) in 
the year post-index.  The list of medications searched in the database included: thiazide 
diuretics (chlorthalidone, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, 
methyclothiazide), potassium-sparing diuretics (amiloride, spironolactone, triamterene), loop 
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diuretics (furosemide, bumetanide, ethacrynate, torsemide), beta-blockers (acebutolol, atenolol, 
betaxolol, bisoprolol, carteolol, carvedilol, labetalol, metoprolol, nadolol, penbutolol sulfate, 
pindolol, propranolol, solotol, timolol), angiotensin converting enzyme (ACE) inhibitors 
(benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, rampril, 
trandolapril), angiotensin-receptor blockers (ARB) (azilsartan, cadesartan, eprosartan, irbesartan, 
losartan, olmesartan, telmisartan, valsartan), calcium channel blockers (CCB) (amlodipine, 
bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldpine, verapamil), alpha 
blockers (doxazosin, prazosin, terazosin), alpha-2 receptor agonists (methyldopa), central 
agonists (clonidine, guanabenz, guanfacine), peripheral adrenergic inhibitors (guanadrel, 
guanethidine, monosulfate, reserpine), and vasodilators (hydralazine, minoxidil). 
b. Clinical variables 
 
Clinical outcomes in this study were categorized into short-term assessments and long-term 
assessments based on the frequency of the assessments in the care of T2DM. 
i. Short term assessments 
Short-term assessments were those variables capable and likely to be addressed at each visit 
including BG (mg/dL), SBP (mmHg), DBP (mmHg), and weight (kg). For these four variables, 
baseline values were measured within 60 days post-index and follow-up values were measured at 
least 180 days post-index, providing for at least 120 days in between measurements. 
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ii. Long term assessments 
Long-term assessments were those variables measured less frequently (due to requiring blood 
draws), with a higher frequency of missing data, including HgA1c (%), LDL cholesterol (mg/dL) 
and total cholesterol (mg/dL). Also, long term assessments are more likely to be measured prior to 
index date. For these three variables, baseline values were measured within 90 days pre- or post-
index and follow-up values were measured at least 120 days post-index, providing for at least 30 
days in between measurements. 
iii. Depression and anxiety severity 
Since the EMR database lacked information to measure depression/anxiety severity such as scales, 
assessments, progress notes, a surrogate measure was utilized. In this study, severity was defined 
through the doses of antidepressant/anti-anxiety treatment. Based on drug monograph or package 
insert of each medication, ‘mild/moderate’ and ‘severe’ dosing ranges were identified for each 
medication for each indication. For this purpose, daily dose of each medication was calculated. 
‘Mild/moderate’ included doses below the maximum daily dose whereas ‘severe’ included the 
maximum dose allowed. The assumption here was that those patients on maximum dose had more 
severe disease compared to other patients on less than maximum dose. Based on this procedure, 
each T2DM patient with comorbid depression and/or anxiety who were on treatment was assigned 
a severity label including ‘mild/moderate’ or ‘severe,’ assessed separately for depression and 
anxiety indications. 
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iv. Presence of pharmacological treatment 
As part of the analysis, patients who were on pharmacological treatment (antidepressant/anti-
anxiety medication) in the first-year post-diagnosis were stratified from those that did not have 
any medications in the EMR. This data isolation was first conducted only on patients with co-
morbid depression and anxiety, and secondly, on the total sample (regardless of their mental illness 
co-morbidity). 
VI. Data analyses 
For purpose of analysis, patients were stratified into four cohorts based on their concomitant 
mental disorder: (1) patients with T2DM only, (2) patients with T2DM and comorbid depression, 
(3) patients with T2DM and comorbid anxiety, and (4) patients with T2DM and comorbid 
depression/anxiety. Microsoft SQL Management Studio (Redmond, WA) and IBM SPSS Statistics 
24 (Armonk, NY) were used for data extraction and statistical analysis, respectively.  Most of the 
variables were measured on categorical scale, with the exception of age, SBP/DBP, LDL, and 
Total cholesterol, which were evaluated on continuous scale. All analyses were evaluated a priori 
at p<0.05.  The data were prescreened for missing values and required assumptions were evaluated 
for univariate and multivariate statistical techniques used for analyses. 
a. Descriptive statistics  
Descriptive analyses were conducted to assess the baseline demographic and clinical factors 
among four cohorts of patients. Each continuous/interval variable was examined for its mean and 
standard deviation. Normality tests, skewness, and kurtosis were carried out on continuous and 
interval-level variables. All interval-level data (dependent variables only) were screened to ensure 
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that the normality assumptions were met before applying statistical tests. For dichotomous and 
nominal-level variables, frequencies and percentages were assessed to determine if the 
requirements for cell sizes are met. Finally, data were screened for missing values and outliers. 
The prevalence rate was calculated for depression and anxiety among patients with T2DM. 
b. Inferential statistics  
Independent samples t-tests (for explanatory variables with two levels), analysis of variance 
(ANOVA) (for explanatory variables with more than two levels), and repeated measure ANOVA 
(to compare group differences over multiple measurements) were conducted on study variables.  
c. Multiple regression analysis 
Statistical analysis techniques such as ANOVA do not adjust for confounding variables. Thus, 
multivariable analyses using logistic regression were conducted to evaluate effect of other 
variables on glycemic goal attainment while controlling for demographic, clinical, and medication-
related variables of interest. Due to the small sample size, the study objectives were revised to 
include only the predictor variables that were empirically important and strongly related to the 
dependent variables.  
 
The logistic regression technique is appropriate for complex and varied data sets and does not 
require normality, linearity, and homoscedasticity assumptions. The assumptions for logistic 
regression models were assessed before running the model. First, binary logistic regression 
requires the dependent variable to be binary. Second, logistic regression requires the 
observations to be independent of each other (eg, the observations should not come from 
repeated measurements or matched data). Third, logistic regression requires there be little or no 
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multicollinearity among the independent variables. Multicollinearity is a common problem when 
estimating linear or generalized linear models, including logistic regression. It occurs when there 
are high correlations among predictor variables, leading to unreliable and unstable estimates of 
regression coefficients. To most data analysts know that multicollinearity is not a good thing but 
there are several situations in which multicollinearity can be safely ignored. 
 Fourth, logistic regression assumes linearity of independent variables and log odds. Although this 
analysis does not require the dependent and independent variables to be related linearly, it requires 
that the independent variables are linearly related to the log odds. Finally, logistic regression 
typically requires a large sample size.  
d. Matching  
Matching was conducted to compare T2DM cases having comorbid depression or anxiety with 
T2DM controls without depression or anxiety. This method was employed to lessen the influence 
of confounding across group analysis due to imbalances in covariates. For this purpose, age (as a 
continuous variable), sex (as a categorical variable, including ‘F’ and ‘M’), HgA1c at baseline (as 
a categorical variable, including <7%, 7-9% and ≥9%) were utilized to shape a three-digit 
matching code for each PID. Then each matching code in depression and anxiety cohorts were 
matched with the same code in the diabetes only cohort. Thus for both depression and anxiety, 
cases (those with the mental illness of interest) were matched with controls (those without mental 
illness) whom had equal age, sex and category of HgA1c at baseline. 
VII. Research Objectives 
In summary, the data analysis conducted for each objective was as below: 
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a. RO 1: Define the demographics and clinical characteristics of patients with T2DM 
with/without comorbid depression/anxiety  
Patients were classified into the aforementioned four cohorts based on their diagnoses. Descriptive 
analyses  were  conducted  to  assess the  baseline demographic and clinical factors, using chi-
square for  categorical  variables  and  ANOVA  for continuous variables.  
b. RO 2: Assess the influence of comorbid depression/anxiety diagnoses upon clinical 
outcomes for T2DM  
Descriptive analyses were conducted to assess the change in seven main outcomes of T2DM 
(HgA1c, BG, SBP, DBP, LDL, total cholesterol and weight) from baseline to follow-up across 
four cohorts of patients in the year post-index, using repeated-measure ANOVA.  
c. RO 3: Assess the influence of the severity of comorbid depression/anxiety diagnoses 
and receiving antidepressants upon clinical outcomes for T2DM and demographic 
comparison 
Descriptive analyses were conducted to assess the change in seven main outcomes between 
‘mild/moderate’ and ‘severe’ cases of comorbid depression and anxiety post-index, using 
repeated-measure ANOVA. In addition, the influence of utilizing antidepressant/anti-anxiety 
treatment was assessed in the patient population (1) among patients with comorbid depression and 
anxiety and (2) among total patients regardless of comorbid diagnoses. The latter was deemed 
necessary as a considerable number of patients with T2DM were taking medications likely for 
indications other than depression and anxiety (eg, neuropathic pain). 
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d. RO 4: Analyze potential predictors of treatment success for patients with T2DM  
The multivariable regression analysis was conducted to evaluate how well certain study variables 
goal attainment in HgA1c as the main outcome of T2DM management. Based on the ACA 
guidelines, HgAlc <7% on follow-up was chosen as the outcome (dependent variable) of interest. 
Independent variables entered into the model included: 
 
Goal HgA1c at follow-up (Y/N) = Age at index (count) + Sex (M/F) + comorbid depression 
(Y/N) + comorbid anxiety (Y/N) + HgA1c at index (count) + Weight at index (count) + 
number of anti-diabetes medications (count)  
 
For this purpose, the analysis includes a dichotomous outcome variable and mixed set of 
predictors (discrete and dichotomous). All variables were continuous with the exception of 
gender, and comorbid depression and/or anxiety.  
VIII. Limitations 
Several limitations are to be noted in this study, categorized as methodological and statistical. 
a. Methodological limitations 
The data analyses were based on a retrospective cohort data. This limitation would be of paramount 
concern if the purpose of the research were to explicitly assert causality, in the sense that a change 
in one variable would cause a change in outcome. However, this was not the purpose of the study. 
Rather, the study purpose was to explore the relationships among patient-related variables and 
overall outcomes of diabetes. Another limitation is that the sampling frame includes patients with 
T2DM visited at primary physicians' clinics located in Western Pennsylvania. Thus, the results 
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may not be generalizable to other patients with T2DM beyond the selected population. Also, they 
may not be generalized to physician offices without EMR capability. Also, since the disease course 
associated with diabetes is complicated, and the present analysis only focuses upon the first-year 
post-diagnosis, the results must be interpreted within this frame of reference.  
 
Depression and anxiety cases were broadly identified through ICD-9-CM codes and different 
subtypes were combined into the broad categories of depression and anxiety. While this was 
performed due to sample size, it should be considered that various subtypes of depression and 
anxiety may have different influences. Also, the diagnoses were considered accurate as recorded, 
although potential misdiagnoses or misclassifications may be present (which this analysis would 
be unable to detect). Another limitation in this regard is including both prevalent and incident cases 
of anxiety and depression. Since these incident cases were newly diagnosed with two serious 
chronic problems their outcomes might be different form prevalent cases of depression and 
anxiety. In fact, the difference would not be detectable by gathering the two in one group. However 
categorizing mental illness cases to prevalent and incident was not conducted due to sample size 
limitation.  
 
Moreover, missing data is an inherent obstacle of EMR analysis. While methods were utilized to 
minimize the impacts, the meaning of missing data was unclear in many cases. In addition, 
incorrect coding-recoding that might had occurred while entering data is another problem, 
particularly when it affected ICD-9-CM coding which is a fundamental part of the current study. 
Also, lack of detailed medication data in the present database made it difficult to ascertain start/stop 
dates of medications, consequently rendering it impossible to provide an understanding of 
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adherence. Patients who are adherent to their treatment will potentially have better clinical 
outcomes than those who are not adherent. Health insurance, income and number of comorbidities 
might be other potential predictors on goal achievement that we could not include due to the nature 
of the database. 
 
Finally, the surrogate definition for severity has several limitations. First, whether patients with 
depression/anxiety received psychotherapeutic (non-pharmacological) treatment was not reflected 
in the database. Therefore, psychotherapy being an effective treatment for these problems would 
not captured as the add-on therapy to reflect severity of the condition. Second, start/stop dates for 
medication utilization were unreliable to assess switching/augmentation of therapies. Thus the 
cases in which severity was reflected on switching the treatment were not captured through the 
proxy utilized here.  
b. Statistical limitations 
One of the limitations was the relatively small sample size which was accounted for by building 
parsimonious models. Further, capturing all important factors in a regression model is nearly 
impossible. Finally, the use of multiple regression only allows for examining direct effects among 
variables and as such indirect effects, which may be relevant in this conceptual model, could not 
be assessed. Even though our multiple regression generates a directional model, it is unable to test 
causal relationships between the variables. It is also not feasible to verify whether the variables of 
interest in the model follow one another chronologically unless data are collected prospectively.
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CHAPTER FOUR – RESULTS 
 
This chapter presents the main findings of the study. Based on concomitant mental disorder, 
patients were categorized into four cohorts: (1) patients with T2DM only, (2) patients with T2DM 
and comorbid depression, (3) patients with T2DM and comorbid anxiety, and (4) patients with 
T2DM and comorbid depression/anxiety. 
I. RO 1: Define the demographics and clinical characteristics of patients with diabetes 
with/without comorbid depression/anxiety  
a. Demographic characteristics 
A total of 1822 predominantly Caucasian patients (47.1% female) with T2DM were evaluated 
(Table 2). Of them, 1410 were diagnosed with T2DM only (77.4%), 148 with T2DM and 
depression (8.1%), 215 with T2DM and anxiety (11.8%) and 49 with T2DM with both depression 
and anxiety (2.7%). Differences in age, gender, race and smoking status were statistically 
significant among the cohorts. The average age in patients with T2DM only was 62.20 (±14.54) 
years while it was younger among the other three cohorts (p=0.001 for comparison across the three 
cohorts). Although patients with T2DM were predominantly male (57.1%), the other three cohorts 
of patients who had a comorbid mental illness were predominantly female (60.0 to 69.4%, 
p<0.001). Patients were predominately Caucasian across cohorts; however, a significant amount 
of data on this variable was missing. Regarding smoking status, the most populated group was 
‘never smokers’ in all four cohorts; rates of ‘current smokers’ were highest in cohorts with anxiety. 
Finally, the average weight of patients in all three cohorts was heavier than 95 kg, and the average 
patient had BMI ≥30 (considered obese).    
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Table 2: Demographic characteristics 
Variables  Total patients (n=1822)  
Diabetes only  
(n=1410)  
Diabetes with 
depression (n=148)  
Diabetes with 
anxiety (n=215)  
Diabetes, depression 
and anxiety (n=49)  p-value  
Age in years, mean (SD)  
0-18  
18-34  
35-44  
45-54  
55-64  
65+  
61.50 (14.47)  
3 (0.1)  
60 (3.3)  
154 (8.5)  
363 (19.9)  
481 (26.4)  
761 (41.8)  
62.20 (14.54)  
3 (0.2)  
41 (2.9)  
118 (8.4)  
265 (18.8)  
354 (25.1)  
629 (44.6)  
60.02 (13.75)  
0 (0)  
5 (3.3)  
10 (6.8)  
39 (26.4)  
45 (30.4)  
49 (33.1)  
58.66 (14.11)  
0 (0)  
12 (5.6)  
19 (8.8)  
52 (24.2)  
64 (29.8)  
68 (31.6)  
58.12 (14.21)  
0 (0)  
2 (4.1)  
7 (14.3)  
7 (14.3)  
18 (36.7)  
15 (30.6)  
  
0.001  
Female sex, n (%)  858 (47.1)  605 (42.9)  90 (60.8)  129 (60.0)  34 (69.4)  <0.001  
Race, n (%)  
Caucasian  
Other  
Missing  
  
1206 (66.2)  
66 (3.6)  
550 (30.2)  
  
936 (66.4)  
56 (4.0)  
418 (29.6)  
  
96 (64.9)  
4 (2.7)  
48 (32.4)  
  
141 (65.6)  
4 (1.9)  
70 (32.5)  
  
33 (67.3)  
2 (4.1)  
14 (28.6)  
<0.001  
Smoking status, n (%)  
Never  
Former  
Current  
Changing  
Missing  
  
836 (45.9)  
491 (27)  
231 (12.7)  
137 (7.5)  
127 (6.9)  
  
664 (47.1)  
391 (27.7)  
167 (11.8)  
91 (6.5)  
97 (6.9)  
  
57 (38.5)  
38 (25.7)  
20 (13.5)  
19 (12.8)  
14 (9.5)  
  
92 (42.8)  
54 (25.1)  
36 (16.7)  
21 (9.8)  
12 (5.6)  
  
23 (46.9)  
8 (16.3)  
8 (16.3)  
6 (12.2)  
4 (8.3)  
0.017  
Weight at index date in kg, mean (SD)  
Missing, n (%)  
96.29 (30.2)  
87 (4.7)  
96.08 (31.9)  
69 (4.9)  
97.15 (24.1)  
8 (5.4)  
96.36 (22.8)  
6 (2.8)  
100.03 (55.3)  
4 (8.2)  0.5  
BMI at index date in kg/m2, mean 
(SD)  
Missing, n (%)  
33.22 (7.11)  
311 (17.1)  
32.96 (9.6)  
221 (15.7)  
34.87 (8.3)  
24 (16.2)  
33.77 (8.18)  
17 (7.9)  
-  
49 (100.0)  0.09  
 
BMI= body mass index; SD= standard deviation
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b. Clinical characteristics 
Among all complications/comorbidities for T2DM, hypercholesteremia (50.8%) and hypertension 
(44.1%) were most prevalent across all four cohorts (Table 3). The mean number of office visits 
per patient in first year post-diagnosis was 4.2 (±2.6) for patients with T2DM only, and 
significantly higher among the other cohorts with comorbid mental illness (p<0.001). The 
prevalence of depression among all patients with T2DM was 197/1822 (10.8%). Moreover, among 
the 148 patients with T2DM and depression, 123 (83.1%) of them were diagnosed with depression 
before or at the same time with T2DM. Among the 49 patients with T2DM and depression/anxiety, 
42 (91.8%) of them were diagnosed with depression before or at the same time with T2DM. The 
prevalence of anxiety among patients with T2DM was 264/1822 (14.5%). Among 215 patients 
with T2DM and anxiety, 179 (83.2%) were diagnosed with anxiety before or at the same time with 
T2DM. Among the 49 patients with T2DM and depression/anxiety, 44 (89.8%) were diagnosed 
with anxiety before or at the same time with T2DM. Examination of HgA1c at baseline 
demonstrated a relatively healthy population with the majoring having HgA1c <7% (39.5 to 49%).  
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Table 3: Clinical characteristics 
Variables  Total patients (n=1822)  
Diabetes only  
(n=1410)  
Diabetes with 
depression (n=148)  
Diabetes with 
anxiety (n=215)  
Diabetes, depression 
and anxiety (n=49)  p-value  
Selected comorbidities, n (%)  
Hypertension 
Hypercholesterolemia  
Neuropathy  
Retinopathy 
Chronic kidney disease  
Heart failure  
Heart disease  
  
804 (44.1)  
926 (50.8)  
68 (3.7)  
15 (0.8)  
46 (2.5)  
69 (3.8)  
178 (9.8)  
  
626 (44.4)  
722 (51.2)  
55 (3.9)  
13 (0.9)  
39 (2.3)  
56 (3.2)  
139 (9.9)  
  
59 (39.9)  
75 (50.7)  
8 (5.4)  
1 (0.7)  
3 (2.0)  
4 (2.7)  
11 (7.4)  
  
99 (46)  
105 (48.8)  
4 (1.9)  
0 (0)  
4 (1.9)  
8 (3.7)  
24 (11.2)  
  
20 (40.8)  
24 (49)  
1 (2.0)  
1 (2.0)  
0 (0)  
1 (2.0)  
4 (8.2)  
  
0.64  
0.92  
0.29  
0.41 
0.54 
0.79  
0.67  
Office visits per patient in first year 
post-diagnosis, mean (SD)  
Missing, n (%)  
  
4.3 (2.7)  
27 (1.5)  
  
4.2 (2.6)  
18 (1.3)  
  
4.7 (2.5)  
4 (2.7)  
  
5.0 (3.4)  
5 (2.3)  
  
4.9 (3.4)  
0 (0)  
<0.001  
Depression diagnosis, n (%)  
Before (or on) diabetes diagnosis  
After diabetes diagnosis  
  
165 (9.0)  
32 (1.8)  
-  
  
123 (83.1)  
25 (16.9)  
-  
  
42 (91.8)  
7 (8.2)  
0.66  
Anxiety diagnosis, n (%)  
Before (or on) diabetes diagnosis  
After diabetes diagnosis  
  
223 (12.2)  
41 (2.2)  
-  
  -  
  
179 (83.2)  
36 (16.8)  
  
44 (89.8)  
5 (10.2)  
0.25  
HgA1c at baseline, n (%)  
<7%  
7-9%  
>9%  
No data available  
  
791 (43.4)  
409 (22.5)  
208 (11.4)  
414 (22.7)  
  
608 (43.1)  
313 (22.2)  
164 (11.6)  
325 (23.1)  
  
74 (50.0)  
24 (16.2)  
9 (6.1)  
41 (27.7)  
  
85 (39.5)  
64 (29.8)  
25 (11.6)  
41 (19.1)  
  
24 (49.0)  
8 (16.3)  
10 (20.4)  
7 (14.3)  
0.001  
 
HgA1c= hemoglobin A1c; SD= standard deviation 
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c. Medication-related characteristics 
The mean number of medications prescribed to each patient in the T2DM only cohort was 9.3 
(±8.2), compared to 12.9 (±9.6), 12.2 (±12.4) and 11.9 (±9.5) among T2DM patients with 
depression, anxiety and both depression and anxiety, respectively (p<0.001) (Table 4). In all four 
cohorts, metformin (alone or with other oral agents) was the most common initial treatment for 
T2DM; rates of insulin use at index were highest among T2DM patients with both depression and 
anxiety. Regarding depression and anxiety treatment at index, the majority of patients in all cohorts 
received SSRIs or SNRIs, in spite of huge number of cases without available data. Depression and 
anxiety treatment differed significantly across cohorts (p<0.001). The percentage of cholesterol 
medications ranged from 42 to 45% among patients with T2DM in the depression and anxiety 
cohorts, while it was the lowest (38.8%) for patients with T2DM and both depression and anxiety. 
On the contrary, use of blood pressure medications were the highest (50%) in this cohort, dropping 
to 43 to 46% in the other diagnosis cohorts.  
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Table 4: Medication related characteristics  
Variables  Total patients (n=1822)  
Diabetes only  
(n=1410)  
Diabetes with 
depression 
(n=148)  
Diabetes with 
anxiety (n=215)  
Diabetes, 
depression and 
anxiety (n=49)  
p-value  
Total medications per patient, mean (SD)  10.0 (9.3)  9.3 (8.2)  12.9 (9.6)  12.2 (12.4)  11.9 (9.5)  <0.001  
Diabetes treatment at index, n (%)  
Metformin   
Metformin and other oral agents  
Only insulin   
Oral agent(s) and insulin  
Other  
No data available  
 
377 (20.7) 
349 (19.2)  
71 (3.9)  
53 (2.9) 
11 (0.6) 
961 (52.7) 
 
280 (19.9) 
284 (20.1)  
49 (3.5)  
39 (2.8)  
5 (0.3)  
753 (53.4) 
 
27 (18.2) 
22 (14.9) 
8 (5.4) 
7 (4.7) 
5 (0.4) 
79 (53.4) 
 
56 (26) 
35 (16.3)  
9 (4.2) 
6 (2.8) 
0 (0) 
109 (50.7) 
 
14 (28.6) 
8 (16.3) 
5 (10.3)  
1 (2) 
1 (2)  
20 (40.8) 
<0.001  
Number of anti-diabetic medications in first year 
post-diagnosis, n (%)  
1  
2-3  
4+  
No data available  
  
  
645 (35.4)  
354 (19.4)  
68 (3.7)  
755 (41.5)   
  
  
500 (35.5)  
268 (19.0)  
52 (3.7)  
590 (41.8)   
  
  
52 (35.1)  
26 (17.6)  
7 (4.7)  
63 (42.6)   
  
  
73 (34)  
47 (21.9)  
8 (3.6)  
87 (40.5)  
  
  
20 (40.8)  
13 (26.5)  
1 (2.1)  
15 (30.6)   
0.88  
Depression/anxiety treatment at index, n (%)  
SSRI or SNRI only  
TCA only  
Benzos only  
Benzo + SSRI/SNRI  
Benzo + TCA  
No data available  
  
125 (6.9)  
16 (0.9)  
71 (3.9)   
36 (2)  
2 (0.1)  
1377 (75.6)  
  
46 (3.3)  
12 (0.9)  
42 (3)  
13 (1)  
1 (0.1)  
1188 (84.3)   
  
40 (27)  
0 (0)  
7 (4.7)  
5 (3.4)  
0 (0)  
63 (42.0)   
  
35 (16.3)  
2 (1)  
19 (8.8)  
12 (5.6)  
0 (0)  
107 (49.8)   
  
4 (8.2)  
2 (4.1)  
3 (6.1)  
6 (12.2)  
1 (2.1)  
19 (38.8)  
<0.001  
Number of antidepressant/anti-anxiety medications 
in first year post-diagnosis, n (%)  
1  
2-3  
4+  
No data available  
  
  
281 (15.4)  
148 (8.1)  
21 (1.2)  
1372 (75.3)   
   
 
154 (10.9)  
63 (4.5)  
6 (0.4)  
1187 (84.2)   
  
  
49 (33.1)  
32 (21.6)  
5 (3.4)  
62 (41.9)   
  
  
65 (30.2)  
38 (17.7)  
8 (3.7)  
104 (48.4)   
  
  
13 (26.5)  
15 (30.6)  
2 (4.1)  
19 (38.8)   
0.05  
Cholesterol medications in first year  
post-diagnosis, n (%)  
  
787 (43.2)  
  
609 (43.2)  
  
67 (45.3)  
  
92 (42.8)  
  
19 (38.8)  0.88  
Blood pressure medications in first year  
post-diagnosis, n (%)  
  
859 (47.1)  
  
675 (46.6)  
  
64 (43.2)  
  
96 (44.7)  
  
24 (50.0)  0.61  
Benzo= Benzodiazepines, SD= standard deviation, SNRI= Serotonin–norepinephrine reuptake inhibitors, SSRI= Selective serotonin 
reuptake inhibitors, TCA= Tricyclic antidepressants
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II. RO 2: Assess the influence of comorbid depression/anxiety diagnoses upon clinical 
outcomes for T2DM 
a. Change in HgA1c 
The change in HgA1c across four cohorts is shown in Table 5. All patient cohorts sustained overall 
lowering of their HgA1c from baseline to follow-up. Diagnosis of anxiety or depression in addition 
to T2DM did not render a significant difference in the pattern of HgA1c change (p=0.16), however, 
the greatest numerical decrease was seen in T2DM patients with both depression and anxiety. Data 
availability for this metric ranged around 52-65% for each cohort, with approximately two HgA1c 
values available for each patient in the year post-diagnosis.  
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Table 5: Change in HgA1c across cohorts 
Groups for HgA1c, % *  Measurements per patient, mean (SD) 
Total patients  
(%)  
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  
Change in 
value (95% CI)  p-value  
Total patients (n=1822)   2.18 (1.04)     1089 (59.8)   7.33 (1.76)    6.59 (1.04)    0.74 (0.64-0.84)   <0.001  
T2DM only (n=1410)   2.18 (1.04)    852 (60.4)  7.35 (1.76)    6.59 (1.01)    0.75 (0.64-0.87)    <0.001  
T2DM/depression (n=148)   2.00 (1.01)    77 (52)  6.93 (1.36)    6.57 (1.10)    0.35 (0.07-0.64)    0.014  
T2DM/anxiety (n=215)   2.30 (1.13)    128 (59.5)  7.34 (1.72)    6.57 (1.19)    0.77 (0.46-1.08)    <0.001  
T2DM/depression/anxiety (n=49)   2.14 (0.92)    32 (65.3)  7.90 (2.60)    6.67 (0.87)    1.23 (0.31-2.15)    0.010  
 
* Between group differences as assessed by repeated measures ANOVA with post-hoc Tukey: HgA1c: p=0.16 
CI= confidence interval; HgA1c= hemoglobin A1c; SD=standard deviation; T2DM= type 2 diabetes mellitus 
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b. Change in BG 
Changes in BG sustained across the four cohorts is shown in Table 6. The overall cohort (driven 
by the T2DM only cohort) demonstrated significant decreases from baseline to follow-up 
(p<0.001). Diagnosis with depression or anxiety in addition to T2DM failed to render any 
significant difference in the pattern of BG change (p=0.400). Patients with data had approximately 
two to three BG measurements available in the year post-diagnosis, but the overall rate of missing 
data for the metric across the sample was high. 
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Table 6: Change in BG across cohorts 
Groups for BG, mg/dL * Measurements per patient, mean (SD)  
Total patients 
(%)  
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  
Change in 
value (95% CI)  p-value  
Total patients (n=1822)  2.42 (1.53)   595 (32.7)  146.55 (69.25)   134.64 (49.72)   11.91 (6.11-17.71)   <0.001  
T2DM only (n=1410)  2.39 (1.54)   455 (32.3)  147.66 (68.13)  136.28 (51.83)   11.38 (4.91-17.86)   <0.001   
T2DM/depression (n=148)  2.39 (1.54)   59 (40)  139.29 (63.18)   132.76 (42.03)   6.53 (-10.58-23.64)   0.440  
T2DM/anxiety (n=215)  2.53 (1.47)   68 (31.6)  142.34 (78.18)   124.05 (37.43)  18.29 (-1.88-38.47)   0.070  
T2DM/depression/anxiety (n=49)  2.60 (1.54)   16 (32.7)  158.38 (83.76)   139.67 (56.84)   18.70 (-33.46-70.87)  0.450   
  
* Between group differences as assessed by repeated measures ANOVA with post-hoc Tukey: BG: p=0.400 
BG= blood glucose; CI= confidence interval; SD=standard deviation; T2DM= type 2 diabetes mellitus 
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c. Change in SBP and DBP 
Analysis of changes in BP (Table 7) demonstrated significant changes in for the total cohort 
(p=0.048) and T2DM only patients (p=0.04), but non-significant changes across other cohorts. 
Interestingly, the overall changes in SBP and DBP differed significantly across different cohorts 
of patients (p=0.019 and p=0.02, respectively), driven by larger changes among patients with 
T2DM and anxiety. The average number of BP measurements per patient was more than four 
across all cohorts and more than 70% of the sample had data available for analysis. 
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Table 7: Change in BP across cohorts 
Groups for BP, mmHg *  Measurements per patient, mean (SD)  
Total patients 
(%)  
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  
Change in 
value (95% CI)  p-value  
Total patients (n=1822)  
SBP 
DBP 
 
4.34 (2.86)   
4.33 (2.85)   
 
1318 (72.3)  
1318 (72.3)   
 
132.12 (15.14)   
79.14 (15.60)  
 
131.44 (14.34)   
78.31 (8.89)  
 
0.68 (-0.17-1.53)   
0.82 (0.01-1.64)   
 
0.117  
0.048  
T2DM only (n=1410)  
SBP 
DBP  
 
4.19 (2.73)   
4.18 (2.73)   
 
1015 (72)  
1015 (72)  
 
132.58 (15.18)   
78.76 (9.03)   
 
131.81 (14.35)   
78.17 (8.76)   
 
0.76 (-0.19-1.73)   
0.59 (.01-1.16)   
 
0.119   
0.040  
T2DM/depression (n=148)  
SBP 
DBP  
  
4.65 (2.55)   
4.65 (2.55)   
  
107 (72.3)  
107 (72.3)  
  
127.91 (15.85)   
77.81 (10.16)   
   
129.15 (14.50)   
77.38 (8.95)   
  
-1.24 (-4.57-2.08)   
0.42 (-1.45-2.30)   
  
0.460  
0.650  
T2DM/anxiety (n=215)  
SBP 
DBP  
  
4.93 (3.37)   
4.92 (3.33)   
  
158 (73.5)  
158 (73.5)  
  
131.64 (13.95)   
81.84 (37.58)   
  
130.18 (13.86)   
79.12 (9.41)   
  
1.46 (-0.81-3.74)   
2.72 (-2.83-8.28)   
  
0.200   
0.330   
T2DM/depression/anxiety (n=49)  
SBP 
DBP  
  
5.02 (4.19)   
5.02 (4.19)   
  
38 (77.6)  
38 (77.6)  
  
133.74 (15.46)   
81.78 (9.59)   
  
133.29 (15.27)   
81.50 (9.42)      
  
0.45 (-5.05-5.96)   
0.27 (-3.41-3.96)   
  
0.860   
0.880   
 
* Between groups differences as assessed by repeated measures ANOVA with post-hoc Tukey: SBP: p=0.019; DBP: p=0.02 
CI= confidence interval; DBP= diastolic blood pressure; SBP= systolic blood pressure; SD=standard deviation; T2DM= type 2 
diabetes mellitus 
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d. Change in LDL 
Table 8 represents the change of LDL in the first-year post-diagnosis in the cohorts. In the total 
sample, the T2DM only cohort, and the T2DM and depression cohort, LDL was significantly 
reduced from baseline to follow-up. These changes were not seen in the T2DM and anxiety cohort 
nor the T2DM depression, anxiety cohort. The change in LDL did not differ across the four 
different cohorts. Approximately two LDL values per patient were available across the sample, 
and data availability varied from 54 to 59% across cohorts. 
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Table 8: Change in LDL across cohorts 
Groups for LDL, mg/dL *  Measurements per patient, mean (SD)  
Total patients 
(%)  
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  
Change in 
value (95% CI)  p-value  
Total patients (n=1822)  2.01 (1.09)   1059 (58.1)  114.25 (36.77)   106.38 (34.22)   7.87 (5.93-9.80)   <0.001  
T2DM only (n=1410)  2.00 (1.10)   830 (58.9)  113.13 (36.58)   105.18 (33.61)   7.94 (5.80-10.08)   <0.001  
T2DM/depression (n=148)  2.01 (1.01)   81 (54.7)  118.85 (39.75)   108.56 (35.83)   10.29 (2.03-18.55)   0.015   
T2DM/anxiety (n=215)  1.98 (1.04)   119 (55.3)  117.71 (34.89)   111.71 (35.52)   6.01 (0.02-11.99)   0.049   
T2DM/depression/anxiety (n=49)  2.17 (1.12)   29 (59.2)  119.55 (40.70)   112.90 (39.99)   6.65 (-6.38-19.69)   0.305   
 
* Between group differences as assessed by repeated measures ANOVA with post-hoc Tukey: LDL: p=0.824. 
CI= confidence interval; LDL= low density lipoprotein; SD=standard deviation; T2DM= type 2 diabetes mellitus 
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e. Change in total cholesterol 
Table 9 shows the change in total cholesterol among four cohorts. Total cholesterol was 
significantly reduced in the overall cohort as well as among T2DM only patients (p<0.001), while 
the change was not statistically significant in other cohorts. Comorbid mental illness did not have 
a significant influence in the pattern of total cholesterol change (p=0.098). The average number of 
measurements per patient for the metric was approximately two, with data availability between 
56-61%.
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Table 9: Change in total cholesterol across cohorts 
Groups for total cholesterol, 
mg/dL *  
Measurements per 
patient, mean (SD)  
Total patients 
(%)  
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  
Change in 
value (95% CI)  p-value  
Total patients (n=1822)  1.96 (1.03)    1060 (58.2)  195.59 (44.90)   184.18 (46.81)   11.40 (8.79-14.01)   <0.001  
T2DM only (n=1410)  1.96 (1.05)    822 (58.3)  194.28 (45.19)   182.43 (46.74)   11.85 (12.93-14.83)   <0.001  
T2DM/depression (n=148)  1.96 (1.01)    87 (58.8)  204.16 (44.56)   192.25 (49.19)   11.90 (2.55-21.26)   0.130  
T2DM/anxiety (n=215)  1.91 (0.95)    121 (56.3)  196.36 (42.40)   188.74 (45.96)   7.61 (-0.06-15.29)   0.052   
T2DM/depression/anxiety (n=49)  2.05 (0.93)   30 (61.2)  203.37 (46.42)   190.43 (43.17)   12.93 (-0.71-26.58)   0.062  
  
* Between group differences as assessed by repeated measures ANOVA with post-hoc Tukey: Total cholesterol: p=0.098. 
CI= confidence interval; SD=standard deviation; T2DM= type 2 diabetes mellitus 
 
 
 77 
f. Change in total weight 
Table 10 shows changes in weight across the cohorts. Significant weight loss was present among 
the overall cohort, T2DM only patients and patients with T2DM and anxiety; patients with T2DM 
and depression (alone or in concert with anxiety) did not have significant changes. Overall, 
comorbid diagnosis did not result in significant differences in weight change (p=0.117) across the 
four cohorts. Data availability for weight was 68 to 71% whilst the average number of 
measurements per patient was greater than four. 
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Table 10: Change in weight across cohorts 
Groups for weight, kg *  Measurements per patient, mean (SD) 
Total patients 
(%)  
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  
Change in 
value (95% CI)  p-value  
Total patients (n=1822)  4.15 (2.60)   1252 (68.7)  95.30 (21.58) 93.98 (21.57) 1.32 (0.99-1.64)  <0.001  
T2DM only (n=1410)  4.03 (2.52)   963 (68.3)  95.00 (21.52)  93.77 (21.64)  1.23 (0.85-1.61)  <0.001  
T2DM/depression (n=148)  4.45 (2.47)   102 (68.9)  96.56 (22.55) 96.16 (22.49)  0.4 (-0.53-1.33)  0.400  
T2DM/anxiety (n=215)  4.63 (3.07)   152 (70.7)  94.66 (20.57) 92.05 (19.81) 2.61 (1.70-3.50) <0.001  
T2DM/depression/anxiety (n=49)  4.53 (2.65)   35 (71.4)  102.78 (24.02)  101.90 (23.14)  0.88 (-1.30-3.06) 0.419   
 
* Between group differences as assessed by repeated measures ANOVA with post-hoc Tukey: Weight: p=0.117 
CI= confidence interval; SD=standard deviation; T2DM= type 2 diabetes mellitus 
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g. Changes in outcomes after matching (depression) 
A total of 111 patients with T2DM and depression were matched on gender, age and baseline 
HgA1c with 111 T2DM only patients. Table 11 presents the result of this matching and 
comparison of outcomes between the groups. HgA1c and BG was significantly reduced among 
depression cases while HgA1c, LDL, and total cholesterol was decreased in patients with T2DM 
only. Between groups differences as assessed by repeated measures ANOVA showed BG as the 
only outcome that was significantly different (p=0.029) between the groups.  
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Table 11: Depression matching on gender, age and baseline HgA1c  
Group *  Total patients (%) 
Baseline value,  
mean (SD)  
Follow-up value, 
mean (SD)  Change in value (95% CI)  p-value  
T2DM/depression (n=111)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
52 (46.8) 
22 (19.8)  
71 (63.9)  
71 (63.9)  
49 (44.1) 
51 (45.9) 
67 (60.3) 
  
6.47 (1.07)  
157.43 (69.33)  
128.58 (14.12)  
77.99 (8.54)  
124.06(46.04)  
210.27 (49.89)  
214.95 (49.07)  
  
6.34 (0.54)  
134.99 (40.99)  
129.12 (14.29)  
77.57 (8.15)  
112.90 (38.89)  
198.84 (50.22)  
213.88 (50.22)  
  
0.13 (0.15-0.69)  
22.44 (1.18-43.69)  
-0.54 (-4.13-3.06)  
0.42 (-1.63-2.46)  
11.16 (-1.58-23.91)  
11.43 (-2.98-25.84)  
1.07 (-1.55-3.69)  
  
0.003  
0.039  
0.767  
0.688  
0.085  
0.117  
0.418  
T2DM only (n=111)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
52 (46.8) 
22 (19.8) 
71 (63.9) 
71 (63.9) 
49 (44.1) 
51 (45.9) 
67 (60.3) 
  
6.86 (1.31)  
125.27 (40.53)  
133.79 (13.32)  
80.37 (7.86)  
121.78 (36.42)  
201.65 (43.15)  
209.76 (39.33)  
  
6.47 (0.55)  
112.12 (18.37)  
131.31 (12.73)  
77.69 (8.32)  
112.73 (36.80)  
187.65 (42.26)  
208.43 (40.15)  
  
0.39 (0.07-0.71)  
13.15 (-4.69-31.00)  
2.48 (-0.65-5.60)  
2.68 (0.54-4.82)  
9.05 (1.57-16.50)  
14 (5.47-22.52)  
1.33 (-0.88-3.54)  
  
0.018  
0.140  
0.120  
0.015  
0.19  
0.002  
0.235  
 
* Between groups differences as assessed by repeated measures ANOVA with post-hoc Tukey: HgA1c: p=0.481; BG: p=0.029; SBP: 
p=0.060; DBP: p=0.286; LDL: p=0.864; Total cholesterol: p=0.248; Weight: p=0.475.  
BG= blood glucose; CI= confidence interval; DBP= diastolic blood pressure; HgA1c= hemoglobin A1c; LDL= low density 
lipoprotein; SBP= systolic blood pressure; SD= standard deviation; T2DM= type 2 diabetes mellitus
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h. Changes in outcomes after matching (anxiety) 
A total of 157 patients with T2DM and anxiety were matched on gender, age and baseline HgA1c 
with 157 T2DM only patients. Table 12 presents the result of this matching. HgA1c, LDL, total 
cholesterol and weight was significantly reduced among patients with T2DM and anxiety cases 
while HgA1c, LDL, DBP, total cholesterol and weight were decreased in T2DM only patients.  
Between groups differences as assessed by repeated measures ANOVA showed LDL as the only 
outcome that was significantly different (p=0.022) between the two groups.  
  
82 
Table 12: Anxiety matching on gender, age and baseline HgA1c 
Group *   Total patients (%) 
Baseline value,  
mean (SD)  
Next value,  
mean (SD)  Change in value (95% CI)  p-value  
T2DM/anxiety (n=157)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
86 (54.7) 
22 (14) 
98 (62.5) 
98 (62.5) 
66 (42)  
65 (41.4) 
94 (59.8) 
  
7.25 (1.82)  
122.97 (32.84)  
131.50 (1.31)  
79.62 (8.48)  
121.08 (37.23)  
196.09 (38.14)  
209.56 (45.57)  
  
6.57 (1.28)  
119.22 (26.74)  
130.65 (1.30)  
79.46 (7.74)  
110.00 (36.67)  
184.49 (41.13)  
202.92 (43.43)  
  
0.68 (0.28-1.05)  
3.75 (-10.57-18.07)  
0.85 (-2.04-3.73)  
0.16 (-1.43-1.74)  
11.08 (3.41-18.73)  
11.6 (1.64-21.55)  
6.64 (3.84-9.43)  
  
0.001  
0.59  
0.562  
0.844  
0.005  
0.023  
<0.001  
T2DM only (n=157)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
86 (54.7) 
22 (14) 
98 (62.5) 
98 (62.5) 
66 (42) 
65 (41.4) 
94 (59.8) 
  
7.15 (1.62)  
116.20 (17.08)  
131.80 (1.29)  
79.77 (7.05)  
106.27 (34.09)  
188.85 (42.22)  
207.12 (50.14)  
  
6.43 (0.96)  
119.95 (26.14)  
130.08 (1.31)  
77.40 (7.74)  
98.23 (34.65)  
176.78 (44.60)  
203.05 (51.35)  
  
0.72 (0.39-1.04)  
-3.75 (-18.03-10.53)  
1.72 (-0.52-3.95)  
2.37 (0.83-3.91)  
8.04 (2.57-13.51)  
12.07 (5.37-18.74)  
4.07 (0.645-7.48)  
  
<0.001  
0.59  
0.131  
0.003  
0.005  
0.001  
0.020  
  
* Between groups differences as assessed by repeated measures ANOVA with post-hoc Tukey: HgA1c: p=0.51; 
BG: p=0.632; SBP: p=0.930; DBP: p=0.333; LDL: p=0.022; Total cholesterol: p=0.263; Weight: p=0.867. 
BG= blood glucose; CI= confidence interval; DBP= diastolic blood pressure; HgA1c= hemoglobin A1c; LDL= low density 
lipoprotein; SBP= systolic blood pressure; SD= standard deviation; T2DM= type 2 diabetes mellitus 
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III. RO 3: Assess the influence of the severity of comorbid depression/anxiety diagnoses 
and receiving antidepressants upon clinical outcomes for T2DM  
 
a. Severity based on medication dose 
Patients were stratified into mild/moderate (n=152) and severe (n=32) disease groups based on 
dosage of antidepressant/anti-anxiety medications. Table 13 shows the descriptive characteristics 
of this subset of patients based on the severity of their mental illness. The mean age of the 
mild/moderate patients was 59.55 (±14.05) years while the mean age of the severe patients was 
59.93 (±16.52) years. Both groups were predominantly female and Caucasian. No significant 
difference was found among the majority of demographic factors. The only factor that significantly 
differed was number of antidepressant/anti-anxiety medications in the first year post-diagnosis 
(p=0.008). In fact, number of antidepressant/anti-anxiety medications was greater in the severe 
patients compared to the mild/moderate patients.  
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Table 13: Descriptive characteristics based on severity of mental illness 
Variables  Mild/moderate (n=152)  Severe (n=32)  p-value  
Age, mean (SD)  59.55 (14.05)  59.93 (16.52)  0.89  
Female sex, n (%)  98 (64.5)  23 (71.9)  0.42  
Race, n (%)   
Caucasian   
Other   
 
93 (61.2)  
59 (38.8)  
 
24 (75)  
8 (25)  
0.13  
Smoking status, n (%)   
Never   
Former   
Current  
Changing   
Missing   
  
55 (36.2)  
44 (28.9)  
25 (16.4)  
17 (11.2)  
11 (7.3)  
  
9 (28.1)  
11 (34.4)  
8 (25.1)  
2 (6.2)  
2 (6.2)  
0.48  
Weight at index in kg, mean (SD)   
Missing, n (%)   
95.07 (23.35)  
5 (3.3)  
103.4 (20.89)  
1 (3.1)  0.06  
Number of antidepressant/anti-anxiety medications 
in first year post-diagnosis, mean (SD)  1.71 (1.15)  2.31 (1.17)  0.008  
Number of anti-diabetic medications in first year 
post-diagnosis, mean (SD)  1.05 (1.22)  1.43 (1.60)  0.13  
HgA1c at baseline, n (%)  
<7%  
7-9%  
>9%  
No data available  
  
87 (57.2)  
27 (17.8)  
11 (9.2)  
24 (15.8)  
  
21 (65.6)  
5 (15.6)  
2 (6.3)  
4 (12.5)  
0.85  
 
HgA1c= hemoglobin A1c; kg= kilograms; SD= standard deviation  
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Table 14 indicates change in clinical outcomes compared between the two severity groups. 
HgA1c, LDL, total cholesterol, and weight were reduced significantly in patients with 
mild/moderate anxiety or depression. On the other hand, neither of these outcomes were 
statistically significant among the severe group. In fact, weight was the only outcome that 
significantly decreased in patients with severe disease. Between groups differences as assessed by 
repeated measures ANOVA did not detect any significant difference between the two severity 
groups, likely a reflection of sample size. 
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Table 14: Clinical outcomes based on severity of mental illness 
Group *  Total patients (%)   
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  Change in value (95% CI)  p-value  
Mild/moderate (n=152)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
90 (59.2)   
59 (38.8)   
118 (77.6)   
118 (77.6)   
83 (54.6)   
82 (53.9)   
115 (75.6)   
  
7.24 (1.61)   
137.61 (54.25)   
130.50 (14.86)   
78.50 (9.89)   
125.20 (40.82)   
207.82 (47.15)   
96.08 (21.61)   
  
6.72 (1.39)   
138.34 (55.93)   
129.42 (14.31)   
78.53 (9.08)   
110.13 (35.05)   
191.17 (50.62)   
94.41 (21.25)   
  
0.52 (0.16-0.87)   
-0.73 (-18.01-16.55)   
1.08 (-2.24-4.40)   
-0.03 (-2.00-1.94)   
15.07 (7.41-22.72)   
16.65 (7.32-25.97)  
1.67 (0.74-2.60)   
  
0.005   
0.933   
0.520   
0.974   
<0.001  
0.001  
0.001   
Severe (n=32)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
19 (59.3)   
10 (31.2)   
24 (75)   
24 (75)   
15 (46.8)   
16 (50)   
22 (68.7)   
  
6.88 (1.50)   
164.25 (156.93)  
127.11 (12.17)   
79.18 (7.49)   
105.93 (23.82)   
187.19 (29.94)  
100.32 (20.76)   
  
6.31 (0.85)   
111.19 (24.38)  
129.66 (17.53)   
79.34 (9.91)   
114.60 (27.14)   
195.31 (39.96)   
97.83 (20.06)   
  
0.57 (-0.09-1.24)  
53.06 (-60.51-166.63)  
-2.55 (-9.57- 4.48)   
-0.16 (-2.00- 1.94)   
-8.67 (-23.66- 6.33)   
-8.12 (-30.35- 14.10)  
2.49 (0.49- 4.49)   
  
0.086   
0.318   
0.462   
0.936   
0.236  
0.448   
0.017   
 
* Between groups differences as assessed by repeated measures ANOVA with post-hoc Tukey: HgA1c: p=0.209; BG: p=0.988; SBP: 
p=0.544; DBP: p=0.669; LDL: p=0.416; Total cholesterol: p=0.475; Weight: p=0.438.  
BG= blood glucose; CI= confidence interval; DBP= diastolic blood pressure; HgA1c= hemoglobin A1c; LDL= low density 
lipoprotein; SBP= systolic blood pressure; SD= standard deviation 
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b. Severity based on presence of treatment (depression/anxiety only) 
Patients were stratified into treated (n=212) and non-treated (n=200) groups (both groups including 
only those with depression and/or anxiety) based on the presence of antidepressant/anti-anxiety 
medications. The average age of the treated patients was 59.34 (±14.31) years while average age 
of not-treated patients was 58.8 (±13.65) years. Both groups were predominantly female and 
Caucasian, but a higher proportion of women were present in the treated group (p=0.02). Smoking 
status differed significantly between the two groups, with higher rates of smoking (current and 
former) in the treated group. Both number of antidepressant/anti-anxiety medications and number 
of anti-diabetes medications in first-year post-diagnosis were significantly higher in treated 
patients. Weight and HgA1c did not differ. 
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Table 15: Descriptive characteristics based on treatment of mental illness  
Variables  Treated (n=212)  Non-treated (n=200)  p-value  
Age, mean (SD)  59.34 (14.31)  58.80 (13.65)  0.69  
Female sex, n (%)  141 (66.5)  112 (56)  0.02  
Race, n (%)   
Caucasian   
Other    
 
138 (65.1)  
74 (34.9)  
 
132 (66)  
68 (34)  
0.84  
Smoking status, n (%)   
Never   
Former   
Current   
Changing  
Missing   
  
79 (37.3)  
61 (28.8)  
38 (18.0)  
21 (9.9)  
13 (6.0)  
  
93 (46.5)  
39 (19.5)  
26 (13.0)  
25 (12.5)  
17 (8.5)  
0.047  
Weight at index in kg, mean (SD)   
Missing, n (%)   
97.08 (22.82)  
7 (3.3)  
97.27 (23.85)  
11 (5.5)  0.93  
Number of antidepressant/anti-anxiety medications in 
first year post-diagnosis, mean (SD)  1.76 (1.12)  0 (0)  <0.001  
Number of anti-diabetic medications in first year post-
diagnosis, mean (SD)  1.11 (1.26)  0.88 (0.96)  0.03  
HgA1c at baseline, n (%)  
<7%  
7-9%  
>9%  
       No data available  
  
127 (59.9)  
37 (17.5)  
16 (7.5)  
32 (15.1)  
  
104 (52)  
38 (19)  
15 (7.5)  
43 (21.5)  
0.68  
 
HgA1c= hemoglobin A1c; kg= kilogram; SD= standard deviation
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Based on the results indicated in Table 16, among treated patients, HgA1c, LDL, total cholesterol, 
and weight decreased significantly in the first-year post-diagnosis. Among non-treated patients, 
HgA1c, BG, total cholesterol, and weight reduced significantly in the first-year post-diagnosis. 
Between groups differences as assessed by repeated measures ANOVA did not find any significant 
difference between the two groups. 
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Table 16: Clinical outcomes based on treatment of mental illness 
Group *  Total patients (%)   
Baseline value, 
mean (SD)  
Next value, mean 
(SD)  
Change in value (95% 
CI)  p-value  
Treated (n=212)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
129 (60.8)   
78 (36.8)   
169 (79.7)   
169 (79.7)   
119 (56.1)   
119 (56.1)   
164 (77.4)  
  
7.21 (1.71)  
139.40 (73.18)   
130.74 (15.16)   
79.33 (9.46)   
119.39 (38.60)   
200.87 (46.10)   
97.38 (21.34)  
  
6.61 (1.24)   
132.47 (51.19)   
130.37 (15.27)   
79.22 (9.36)   
110.20 (34.58)   
190.75 (48.24)   
95.78 (21.14)  
  
0.6 (0.30-0.89)   
6.93 (-11.53-25.39)   
0.37 (-2.28-3.02)   
0.11 (-1.43-1.67)   
9.19 (3.15-15.22)   
10.12 (2.67-17.56)   
1.6 (0.82-2.37)  
  
<0.001   
0.457   
0.784   
0.880   
0.003   
0.008   
<0.001  
Non-treated (n=200)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
108 (54)   
62 (31)   
134 (67)   
134 (67)   
110 (55)   
119 (59.5)   
125 (62.5)  
  
7.38 (1.87)   
147.42 (72.91)   
130.39 (14.69)   
81.77 (40.83)   
117.22 (35.90)   
199.32 (41.32)   
94.90 (22.38)  
  
6.55 (0.95)   
125.35 (25.67)   
130.00 (12.96)   
78.28 (9.25)   
111.33 (37.81)   
189.73 (45.25)   
93.26 (21.69)  
  
0.83 (0.46-1.18)   
22.07 (3.83-40.30)   
0.39 (-1.92-2.71)   
3.49 (-3.02-9.99)   
5.89 (-.94-12.72)   
9.59 (1.64-17.52)   
1.64 (0.55-2.72)  
  
<0.001   
0.018   
0.738   
0.292   
0.91   
0.018   
0.003  
 
* Between groups differences as assessed by repeated measures ANOVA with post-hoc Tukey: HgA1c: p=0.711; BG: p=0.953; SBP: 
p=0.802; DBP: p=0.688; LDL: p=0.903; Total cholesterol: p=0.805; Weight: p=0.327  
BG= blood glucose; CI= confidence interval; DBP= diastolic blood pressure; HgA1c= hemoglobin A1c; LDL= low density 
lipoprotein; SBP= systolic blood pressure; SD= standard deviation 
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c. Severity based on presence of treatment (all patients) 
The total patient population (n=1822) was stratified into patients who received antidepressant/anti-
anxiety treatment (n=400) and patients who did not receive antidepressant/ anti-anxiety treatment 
(n=1422), regardless of comorbid mental illness. Based on Table 17, both were predominantly 
Caucasian but the former group had a significantly higher fraction of female patients (p<0.001). 
Both number of antidepressant/anti-anxiety medications and number of anti-diabetes medications 
in first year post-diagnosis were significantly higher in treated patients (p<0.001).  
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 Table 17: Descriptive characteristics based on antidepressant/anti-anxiety treatment  
Variables  
Received antidepressant/ 
anti-anxiety medication 
(n=400)  
No antidepressant/ 
anti-anxiety 
medication (n=1422)  
p-value  
Age, mean (SD)  60.32 (14.29)  61.83 (14.51)  0.06  
Female sex, n (%)  250 (62.5)  608 (42.8)  <0.001  
Race, n (%)   
Caucasian   
Other    
Missing  
  
258 (64.5)  
138 (34.5)  
4 (1.0)  
  
948 (66.6)  
469 (33)  
5 (0.4)  
0.42  
Smoking status, n (%)   
Never   
Former   
Current  
Changing  
Missing   
  
168 (42)  
102 (25.5)  
59 (14.8)  
41 (10.2)  
30 (7.5)  
  
668 (47)  
389 (27.4)  
172 (12)  
96 (6.8)  
97 (6.8)  
0.03  
Weight at index in kg, mean (SD)   
Missing, n (%)   
95.45 (22.46)  
18 (4.5)  
96.24 (29.61)  
69 (4.8)  0.62  
Number of antidepressant/anti-anxiety 
medications in first year post-
diagnosis, mean (SD)  
 
 
1.65 (1.01)  
 
 
0 (0)  
<0.001  
Number of anti-diabetic medications in 
first year post-diagnosis, mean (SD)  
 
1.16 (1.27)  
 
0.90 (1.04)  <0.001  
HgA1c at baseline, n (%)  
<7%  
7-9%  
>9%  
      No data available  
 
233 (58.3) 
73 (18.3) 
31 (7.6) 
63 (15.8) 
 
764 (53.7) 
289 (20.3) 
136 (9.6) 
233 (16.4) 
0.23 
 
HgA1c= hemoglobin A1c; kg= kilogram; SD= standard deviation  
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Table 18 shows the change in clinical outcomes and the comparison between patients receiving 
antidepressant/anti-anxiety treatment versus patients not receiving antidepressant/ anti-anxiety 
treatment. Among T2DM patients who received antidepressant/anti-anxiety treatment, HgA1c, 
LDL, total cholesterol, and weight reduced significantly (p<0.01). On the other hand, regarding 
T2DM patients who did not receive antidepressant/anxiolytic treatment, HgA1c, BG, LDL, total 
cholesterol, and weight reduced significantly. Based on between groups differences as assessed by 
repeated measures ANOVA, total cholesterol was the only outcome changed significantly 
(p=0.039) based on receiving antidepressant/anti-anxiety treatment. 
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Table 18: Clinical outcomes based on antidepressant/anti-anxiety treatment  
Group *  Total patients (%)   
Baseline value, 
mean (SD)  
Follow-up value, 
mean (SD)  Change in value (95% CI)  p-value  
Received antidepressant/anxiolytic (n=400)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
229 (57.3)   
123 (30.8)   
316 (79)   
316 (79)   
212 (53)   
214 (53.5)   
296 (74)   
  
7.35 (1.75)  
144.97 (81.09)  
131.01 (15.57)  
79.13 (9.32)  
119.74 (42.13)  
202.81 (51.52)  
96.68 (21.35)  
  
6.58 (1.00)  
135.82 (52.12)  
131.08 (15.53)  
78.57 (9.41)  
106.78 (35.31)  
187.14 (47.47)  
95.64 (21.54)  
  
0.77 (0.65- 0.88)  
9.15 (-6.78- 25.08)  
0.07 (-1.97- 1.84)  
0.56 (-0.50- 1.63)  
12.96 (8.03- 17.87)  
15.67 (9.86- 21.48)  
1.04 (0.38- 1.68)  
  
<0.001  
0.258  
0.948  
0.302  
<0.001  
<0.001  
0.002  
No antidepressant/anxiolytic (n=1422)  
HgA1c, %  
BG, mg/dL  
SBP, mmHg  
DBP, mmHg  
LDL, mg/dL  
Total cholesterol, mg/dL  
Weight, kg  
  
860 (60.5)   
472 (33.2)   
1002 (70.5)   
1002 (70.5)   
847 (59.6)   
846 (59.5)   
956 (67.2)   
  
7.28 (1.81)  
146.97 (65.90)  
132.47 (14.99)  
79.14 (17.11)  
112.88 (35.20)  
193.76 (42.91)  
94.88 (21.64)  
  
6.63 (1.16)  
134.33 (49.13)  
131.56 (13.95)  
78.23 (8.80)  
106.28 (33.96)  
183.44 (46.65)  
93.47 (21.57)  
  
0.65 (0.42- 0.88)  
12.64 (6.58- 18.68)  
0.91 (-.029- 1.85)  
0.91 (-0.11- 1.92)  
6.6 (4.51-  8.68)  
10.32 (7.40- 13.24)  
1.41 (1.03- 1.78)  
  
<0.001  
<0.001  
0.058  
0.081  
<0.001  
<0.001  
<0.001  
 
* Between groups differences as assessed by repeated measures ANOVA with post-hoc Tukey: HgA1c: p=0.883; BG: p=0.959; SBP: 
p=0.228; DBP: p=0.808; LDL: p=0.131; Total cholesterol: p=0.039; Weight: p=0.162  
BG= blood glucose; CI= confidence interval; DBP= diastolic blood pressure; HgA1c= hemoglobin A1c; LDL= low density 
lipoprotein; SBP= systolic blood pressure; SD= standard deviation 
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IV. RO 4: Analyze potential predictors of treatment success for patients with T2DM  
As stated in method section, the multiple regression analysis was conducted to evaluate how well 
certain study variables goal attainment in HgA1c as the main outcome of T2DM management. 
Table 19 shows the relative strength of each individual predictor. The regression model shows 
that age at index, HgA1c at index and number of medications for diabetes were significant 
predictors of HgA1c goal attainment. In this model, co-morbid depression and anxiety did not 
reach the level of significance. 
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Table 19: Logistic regression predicting goal HgA1c with separate comorbid depression and 
anxiety 
 p-value OR 95% CI Lower Upper 
Age at index 0.000 1.026 1.013 1.039 
Sex (M/F)  0.729 0.941 0.669 1.325 
HgA1c (index) 0.000 0.573 0.517 0.636 
Weight at index (kg) 0.609 0.998 0.990 1.006 
Number of diabetes meds 0.019 0.937 0.888 0.989 
Comorbid depression (Y/N)  0.235 0.695 0.381 1.267 
Comorbid anxiety (Y/N) 0.091 0.580 0.309 1.091 
 
CI= confidence interval; F=female; HgA1c= hemoglobin A1c; kg= kilogram; M=male; N= no; 
OR= odds ratio; Y= yes 
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In the next model indicated in Table 20, all variables were similar with the previous regression 
model. The only difference was two groups of comorbid depression and comorbid anxiety were 
summed into one group of ‘mental illness (Y/N)’ as one single categorical variable. When 
examining the relative strength of each individual predictor through this model, it was shown that 
age at index, HgA1c at index and number of diabetes medications along with being diagnosed with 
mental illness were significant predictors of HgA1c goal attainment. 
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Table 20: Logistic regression predicting goal HgA1c with combined comorbid depression and 
anxiety 
 p-value OR 95% CI Lower Upper 
Age at index 0.000 1.026 1.013 1.039 
Sex (M/F)  0.674 0.929 0.660 1.308 
HgA1c (index) 0.000 0.575 0.519 0.638 
Weight at index (kg) 0.594 0.998 0.990 1.006 
Number of diabetes meds  0.003 0.929 0.885 0.975 
Comorbid mental illness (Y/N) 0.004 0.487 0.298 0.797 
 
CI= confidence interval; F=female; HgA1c= hemoglobin A1c; kg= kilogram; M=male; N= no; 
OR= odds ratio; Y= yes 
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CHAPTER FIVE – DISCUSSION 
 
This chapter provides a discussion of the study findings, which examined the impact of co-morbid 
depression and anxiety upon clinical outcomes in patients with T2DM. This chapter begins with a 
review of the research objectives along with discussion of the main findings. After this, the study 
sample, as well as the study findings are discussed and compared with previous research. The last 
part of this chapter evaluates the findings for research objectives and presents discussions on the 
study implications, future research, study limitations, and conclusions. 
 
The first research objective was to identify the sample characteristics associated with depression 
and anxiety, eventually influencing the outcomes results. Describing the demographic and 
medication-related and clinical factors provided an analysis of the survey of the patient sample 
and the potential applicability to other populations. The second research objective was to assess 
the change in clinical outcomes of diabetes regarding depression and anxiety. This was assessed 
within the first-year post-diagnosis to identify any differences associated with comorbid mental 
illness. The third research objective concentrated on assessing the impact of the severity of 
comorbid depression and comorbid anxiety on clinical outcomes, using surrogate measures such 
as severity measure. Understanding the severity of concomitant mental illness with clinical 
complications may provide a better idea of how to effectively manage patients. Lastly, the final 
research objective focused specifically on potential predictors of HgA1c goal attainment in the 
sample, as ascertained in a regression model. 
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I. Findings for Research Question 1 
In general, patients with comorbid mental illness were significantly younger than T2DM only 
patients. Across the cohorts, patients with depression and anxiety were the youngest, followed by 
patients with anxiety, and patients with depression, respectively. Three patients out of T2DM only 
in the whole patient population were less than 18 years old. However, out of a total cohort of 1410 
patients, these patients were unlikely to affect the analysis of changes in clinical outcomes. It is 
likely that these three patients potentially might have been type 1 DM that had been actually 
miscoded. Patients without any comorbid mental illness were more likely to be male, whereas 
patients with comorbid mental illness tended to be female. This finding is in line with previous 
literature revealing gender is a predictor for depressive symptoms within patients with T1DM and 
T2DM.132 Another study conducted on patients with DM and depression revealed that a higher 
proportion of patients with DM and depression were female (63.7 vs 46.3%; p<0.001) and they 
were generally younger than those without concomitant depression (mean age 57.7 vs 62.2 years; 
p<0.001).133 Regarding anxiety, a study conducted in India showed that major predictors for a 
severe form of depression and anxiety among T2DM cases were age, female sex, insulin therapy, 
retinopathy, nephropathy, and ischemic heart disease.95 Consequently, anxiety is shown to be more 
common among female patients with T2DM as well. These findings need to be interpreted within 
the context of the fact that the differences between females and males in anxiety and depression 
prevalence is a function of under-diagnosis and reporting of depression and anxiety in men. 
 
  
Analysis of differences in race among cohorts in this study was difficult due to a large degree of 
missing data for the variable. In other prevalent literature, among those with DM in UK, South 
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Asians reported less depressive symptoms than Caucasians patients with diabetes.134 A similar 
conclusion was found in the US, with Asians and African-Americans with DM having less 
depressive symptoms than non-Hispanic Caucasians with DM.135 In line with findings regarding 
depression, in a large population based sample in the US, anxiety was related to ethnicity in 
patients with DM, with Hispanic and non-Hispanic blacks reported more anxiety symptoms than 
other ethnic backgrounds.136 These results do appear to correlate with trends in the present study 
but the Caucasian dominancy of the population, as well as the missing data made this difficult to 
assess.  
 
According to a meta-analysis,137 depression is associated with increased rate of DM complications. 
However, in the present study, the prevalence of DM complications was not statistically different 
among the four cohorts in our study. This is likely an influence of the nature of the cohort, which 
was in the first-year post-diagnosis, and too early in the disease course to have demonstrated such 
complications. As expected, the prevalence of microvascular and macrovascular complications 
was <10% across our study sample, and HgA1c was low even at index date. 
 
The average number of medications per patient was significantly higher in T2DM patients with 
depression and anxiety. This is due to patients with comorbid mental illness having the potential 
for additional pharmacological treatment besides their T2DM. Though weight and BMI were not 
statistically different among cohorts, as expected, average weight was elevated (>96 kg) and the 
average BMI was categorized as obese (≥30). These variables, while not contributing new 
information, provide a logical verification of expected trends within the study sample. 
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Depression is an important but frequently undiagnosed comorbidity in T2DM. In previous studies, 
up to 20% of patients with DM have comorbid major depressive disorder.138 The prevalence rate 
of depression is reported to be higher in T1DM (12% vs 3.2%) as well as T2DM (19.1% vs 10.7%) 
compared with people without DM.139 Another study reported that the prevalence of depression 
among patients with T2DM is twice than in general population (19.1% vs 10.7%).139 Several 
studies have shown that sociodemographic factors can be predictive of having depression among 
T2DM patients, including female sex, younger age, lower socioeconomic status, being unmarried, 
having poor social support, and being of certain ethnicities.140 Our present study found a much 
lower prevalence rate of depression (10.8%) among patients with T2DM than in other literature. 
However, one study was careful to identify that while the lifetime prevalence or “history” of 
depression in patients with diabetes was nearly 23%, whereas the prevalence of “recent” (12-
month) depression was 8%.141 This provides a closer estimate to our results. In this study, 
concomitant mental illness was primarily diagnosed before T2DM index date.  
 
As for anxiety, a study conducted on T2DM patients in Croatia concluded that pathological anxiety 
measured by Hamilton Anxiety Rating Scale was more prevalent in patients with DM than the 
patients in control group (p=0.002).134 Moreover, a study conducted on patients with T2DM in 
tertiary care center reported that a significantly larger proportion of patients with DM had 
depression (26.3% vs 11.2%; p=0.001), anxiety (27.6% vs 12.7%; p=0.001) and comorbid 
depression and anxiety (21.0% vs 7.3%; p=0.001) as compared to healthy controls, with a higher 
prevalence in women than men.95 These estimates are larger than the prevalence of anxiety in 
present study (14.5%). However the fact that female gender is related to higher prevalence of 
anxiety amongst patients with T2DM is consistent with the findings already mentioned. One 
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reason for high prevalence of anxiety among patients with T2DM may be that the diagnosis and 
treatment processes involved with T2DM can induce anxiety in patients who are already 
susceptible. In the present study, patients are newly diagnosed with T2DM, and perhaps not 
overwhelmed yet with treatment. Following up the patient population beyond one year may lead 
to results more in line with previous literature.  
  
Type of anti-diabetic treatment at index was significantly different across cohorts. This finding is 
in line with another retrospective study conducted in the USA showing significant differences in 
the type of antidiabetic medication between patients with DM and depression and those without 
depression.142 In fact, though the way DM medications were categorized was different between 
two studies, similarities can be found in terms of type of anti-diabetic treatment. For instance, in 
the previous study, patients with DM and depression had higher rate of "insulin only" regimen 
during the evaluation period than patients without depression, and in current study, the rate of 
"insulin only" regime was higher among patients with depression. In the present study, in terms of 
frequency of initial anti-diabetic prescription, patients with T2DM and comorbid mental illness 
most frequently received "metformin only" as initial therapy, while in T2DM only cohort, the most 
frequent initial therapy was "metformin in combination with other oral agents". This did not appear 
to align with the HgA1c at index, which should influence the initial treatment decision. However, 
there was a significant number of patients where treatment at index was unable to be discerned. 
This may be due to initial treatment with non-pharmacological treatments such as diet and exercise. 
However, the number of antidiabetic medications did not statistically differ among the cohorts.  It 
also could be due to patients receiving pharmacological therapy from other physicians, such as 
endocrinologists.  
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Antidepressant medications are most often prescribed in primary care.143 The type of 
depression/anxiety treatment at index was significantly different across groups. SSRI or SNRI 
group was the most frequently prescribed among depression and anxiety cohorts whilst 
benzodiazepines in combination with SSRI/SNRI was the most frequently prescribed group in 
patients with both depression and anxiety. The pharmacological classes of antidepressants most 
commonly prescribed in this study resembled another study in Canadian primary care.144 In 
addition, as expected average number of antidepressant/anti-anxiety medications in first year post-
diagnosis was higher with patients with a diagnosis mental illness. Even without comorbid mental 
illness, T2DM only patients might utilize antidepressant/anti-anxiety medications for other 
indications, such as diabetic neuropathy.  
 
The average number of office visits per patient in first year post-diagnosis was significantly higher 
in patients with anxiety and patients with both anxiety and depression. This finding is expected 
considering the nature of anxiety disorder, where patients may have greater need to visit the 
physician due to frequent stress regarding their health status.145  
 
II. Findings for Research Question 2 
 
Regarding the total population (raw analysis), all clinical outcomes except for SBP statistically 
improved from baseline to follow-up. T2DM only patients followed the same patterns of change 
as total population. Among patients with depression and anxiety, the rate of improvement from 
baseline to follow-up fell. In patients with T2DM and depression, only HgA1c and LDL 
significantly improved, whilst among patients with T2DM and anxiety, HgA1c and weight were 
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the only outcomes that improved. Among T2DM patients with both depression and anxiety was 
the only outcome that made progress. Thus, HgA1c was the only outcome successfully reduced 
across all four cohorts; logically, glycemic control would be the main clinical focus for these 
patients, with other outcomes considered important, but secondary. This finding was likely 
influenced by sample size. The sample size of 1822 patients across the total sample indicated 
statistical differences as opposed to 49 patients in the T2DM, depression and anxiety cohort due 
to larger sample sizes increasing the probability of finding a statistical difference.  Basically, since 
the smaller groups were affected by sample size, the level of significance was met in less cases 
and numbers were not still as robust as the T2DM only cohort.  
 
According to one study conducted on 42 adult African-Americans, depression (r=0.38, p=0.03), 
anxiety (r=0.56, p=0.001), and stress (r=0.36, p=0.04) were positively correlated with HgA1c. 
Anxiety was the strongest correlate, followed by depression and stress assessment.146 In recent 
years, there have been many studies presenting evidence that comorbid depression among 
individuals with T2DM is associated with poor clinical outcomes. A meta-analysis of 24 studies 
found that depression was significantly associated with poor glycemic control in individuals with 
T2DM.85 These findings are not in line with the result of between group analysis that did not show 
any difference between patients with depression and anxiety and patients without depression and 
anxiety. Inadequate sample size most likely compromised the statistical test. 
 
Among four cohorts, blood pressure (including SBP and DBP) was the only outcome that were 
significantly different between groups. Although the study was unable to determine the reasons 
behind this, there are several plausible explanations. First, data availability was the highest for 
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blood pressure across all four cohorts, rendering larger sample sizes for analysis. Second, patients 
may be more sensitive about controlling blood pressure since keeping track of BP is easier and it 
can be measured easily at home.  
 
Since significant differences in sex, age and HgA1c were present, a matching procedure was 
adopted. As mentioned in method section, matching was conducted on the three variables that were 
mainly predicting the outcomes according to the literature. Other categories such as treated versus 
non-treated could have been used but would result in sample size shrinkage. Based on the findings 
of matching, among T2DM patients with comorbid anxiety, HgA1c, LDL, total cholesterol and 
weight statistically improved, while among patients with T2DM only, HgA1c, DBP, LDL, total 
cholesterol and weight improved. LDL was the only outcome that improved to a greater degree in 
T2DM patients with comorbid anxiety, compared to T2DM only patients. The reason for this is 
unknown, although there may be some hypothesized influence of anxiety symptoms leading to 
more attention (and worry) associated with diabetes care. However, if this were broadly true, it 
would be expected that patients with anxiety would be improved across multiple outcomes 
compared to patients without anxiety. It is extremely difficult to speculate about this finding. 
 
Similar to the findings of matching, among T2DM patients with comorbid depression, HgA1c and 
BG improved, while among T2DM only patients, HgA1c, LDL and total cholesterol improved 
from baseline to follow-up. BG improved to a larger degree among T2DM patients with depression 
compared to T2DM only. Overall, the results of matching can confirm the conclusion that HgA1c 
improvement was seen across all patients with T2DM, and comorbid mental illness produced 
varying effects across other clinical outcomes, hampered by sample size in this analysis. 
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III. Findings for Research Question 3 
The analyses using pharmacological treatment doses as a surrogate measure for severity showed 
that patients with less severe mental illness had improvements in four clinical outcome categories 
(HgA1c, LDL, total cholesterol and weight), while patients with more severe mental illness only 
demonstrated improvements in weight. This would support the underlying hypothesis that higher 
doses of treatment may indicate more severe mental illness, and a higher level of disability that 
could affect adherence to medication and lifestyle modifications for T2DM. From a statistical point 
of view, the sample size was bigger for less severe patients, which may have influenced the results. 
This may also have influenced the results of the between-group analyses, where no statistical 
difference was found across clinical outcomes between more severe and less severe patients.  
 
As the other part of the third objective, the influence of pharmacotherapy of comorbid 
depression/anxiety diagnosis upon clinical outcomes for diabetes was assessed. The importance of 
this objective is the mixed results in the published literature which was discussed in the second 
chapter. For this purpose, patients with comorbid mental illness were divided first to those who 
received antidepressant versus those who did not, and secondly among the total patient population 
to these groups regardless of presence of comorbid mental illness. The reason for this dual 
stratification was to investigate pharmacological treatment (beyond mental illness diagnosis) as a 
potential influential factor in outcomes. In both cases, patients receiving antidepressant treatment 
were more likely to be female, in line with previous research findings. In addition, in both cases 
smoking status statistically differed between the two groups. The percentage of never smokers was 
lower and current smokers was higher in the treated groups. Plus, in both categories, the number 
of anti-diabetic medications in first year post-diagnosis was higher. These finding may render two 
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potential explanations. First, patients who receiving antidepressants may be more comfortable with 
pharmacological therapy, rendering higher physician comfort in prescribing anti-diabetic 
medications. Second, patients who received antidepressants have a more severe disease process, 
rendering greater need for anti-diabetic medication. Regardless, no difference was found in clinical 
outcomes between patients receiving antidepressant treatment vs non-treated patients.  
 
In a research conducted on patients with DM in India, a significant decline in mean Hamilton 
Depression Rating Scale scores was observed during escitalopram therapy, with corresponding 
declines in FBG, post-prandial BG and HgA1c.110 According to an abridged Cochrane review146 
pharmacological intervention (mainly SNRIs) had a moderate beneficial effect on glycemic control 
at the end of treatment. The findings of present study did not agree with this finding. One 
explanation can be that one year following the first year of diagnosis is not sufficient time to see 
the influence of antidepressant therapy considering the patient population was relatively healthy 
in terms of clinical outcomes at baseline. Additionally, the time between baseline and follow-up 
was an even shorter period of time. The other explanation can be the fact that just being prescribed 
an antidepressant did not mean that patient would take them according to directions, or at all. In 
other words, the fact that there was no control of or assessment of medication adherence can affect 
the result. Based on a randomized controlled pilot trial conducted on older African-American 
patients with T2DM, participants who had 80% or greater adherence to an oral hypoglycemic and 
an antidepressant had lower levels of HgA1c and fewer depressive symptoms compared with less 
adherence.147  
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Lastly, other factors such as counselling and behavioral therapy may have significant influence, 
but this effect would be unknown since there was no way it could be captured through current 
EMR database.  
 
IV. Findings for Research Question 4 
When examining the relative strength of each individual predictor through the final regression 
models, age at index, HgA1c at index and number of anti-diabetic medications were significant 
predictors of HgA1c goal attainment. In the former model, concomitant anxiety and depression 
did not emerge as significant predictors. In the latter model where they were both categorized as 
one group of mental illness, all the previous factors along with this composite predictor were 
significant predictors of HgA1c goal attainment. This can be a result of increasing sample size 
which made the variable more comparable to the other variables in the model.  
 
This finding is in line with previous research. The existing literature highlights a significant 
prognostic association of depression with impaired glycemic control in patients with DM.148 The 
co-existence of depression and DM has been associated with poor self-management and twofold 
increased risk of cardiovascular events, notably stroke, and premature mortality.149,150 In a 
retrospective cohort study using claims data, DM patients with depression symptoms were less 
likely to be at their glucose goal (43% vs 50%, p=0.0176).151 In a study conducted on the elderly 
in China, geriatric patients with depression had more frequent self-reported hypoglycemic events 
(17 vs 6%, p=0.03) and were less likely to attain all three treatment targets (0 vs 16%, p=0.004) 
than those without depression.152 In the contrary, there are opposite findings as well. According to 
a study conducted on patients with T2DM in the Basque Country, there was no association between 
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the presence of depression and glycemic control.99 With respect to anxiety, mixed results were 
also found about glycemic control. According to one study, HgA1c levels were not significantly 
different in those with or without anxiety.153 However, a meta-analysis also reported that the 
existing literature suggests that anxiety disorders are associated with hyperglycemia in diabetic 
patients.154 The contradicting results regarding both comorbidities is in line with the fact that a 
definitive result is difficult to conclude. The problem here can be the fact that the individual effect 
of depression and anxiety on clinical outcomes of DM was not distinguished from the effect of 
treating depression and anxiety. Perhaps that is why gathering both comorbidities in one group and 
increasing the sample size led to a significant finding. Further studies are recommended in this 
area with larger sample size. Having control over more side variables could be another helpful way 
to reach to a powerful model. 
V. Implications of research 
The study results provide insight into clinical outcomes for T2DM stratified by the presence of 
comorbid depression and anxiety, as well as HgA1c goal attainment and medication prescribing 
patterns in patients with concomitant depression and anxiety, with a focus on patients in primary 
care. The study results can be interpreted in the context of medical practice and can be useful in 
the following aspects.  
 
Firstly, based on the results obtained from this current study, the consistent clinical outcome of 
improvement across patients with T2DM (regardless of the presence of mental illness) in the first 
year post-diagnosis was HgA1c. This suggests that other outcomes may require additional focus 
by the physician to achieve goals. Despite not being a main glycemic outcome, endpoints such as 
BP, weight and lipids are very important for the overall broader approach to treatment of T2DM 
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in primary care. Also, may need a longer time period of stress and coping with the disease for 
symptoms of anxiety and depression to appear. Unfortunately, it is a moving target because other 
life issues can precipitate or exacerbate symptoms acting as an additive effect to the stress of 
coping with diabetes. 
 
Secondly, the study suggests nuanced differences in clinical experiences of T2DM patients with 
comorbid depression or anxiety. The ability of this study to make solid conclusions was limited 
by sample size, however there are some mitigating circumstances. Often it is common for 
clinicians to think of ‘mental illness’ as a global disease group, but it is prudent to recognize the 
differences in each condition and the resulting influence on physical diseases such as T2DM can 
be varied. For instance, due to the serious nature of T2DM, patients with comorbid anxiety may 
be more likely to commit to treatment due to feeling anxious and worried. In particular, this study 
suggests that severity of mental illness is a key consideration. By understanding the implications 
of mental illness more deeply, healthcare professionals can aid patients in their treatment journey 
to attain their clinical goals through empirically guided expertise.  
 
Additionally, this study empirically tested associations that influenced HgA1c goal attainment in 
T2DM patients and lends support for further investigation of such a model. The model used in this 
study was preliminary but identified important contributors and has provided a springboard for 
more comprehensive models to be built, with special consideration given to T2DM patients with 
mental illness to attain their glycemic treatment goals. Further work could improve on this model 
by incorporating the predictive influence of lifestyle interventions as well as social determinants 
of health. 
 112 
 
Lastly, the use of EMR for outcomes research in this study is a demonstration of the utility of this 
type of data to help improve the overall process of care, especially in primary care practice.  EMR 
provides a patient-centered data and patients with multiple conditions that can be identified easily.  
Thus, physicians can treat patients taking all the multiple conditions into account. This information 
gathered from EMR plays a vital role in designing a patient-centered approach, i.e., treatment 
strategies tailored specifically based on the health status of each patient.  EMR provides both pre- 
and post-diagnosis information which can be helpful for improving follow-up of test results and 
overall health status.   
VI. Suggestions for future research 
Due to the limitation of sample size in this current study, it is possible that a number of findings 
were subject to type II errors and could have better assessed with a larger and more diverse sample. 
Hence, future research could replicate this study in a larger and more heterogeneous sample of 
patients with T2DM and comorbid depression and anxiety. Perhaps, such replications could also 
allow for exploration of other predictors (not available in this study, such as different races and 
medication adherence) in HgA1c goal attainment and other associations between being diagnosed 
with depression and anxiety upon clinical outcomes of DM. In order to more fully elucidate the 
effect on comorbid depression and anxiety, future studies should consider including the presence 
of psychotherapy treatment, health insurance, income, number of comorbidities and medication 
adherence as potential correlates or mediating factors in the outcomes. It is worthwhile to mention 
that near-significant results in this research can be areas of further investigation in the emerging 
research in the future. Finally, future studies could use more robust methodologies to 
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simultaneously test all of the casual relationships among the factors that comprise overall clinical 
outcomes.  
VII. Study limitations 
Limitations are inevitable in all studies, and it is important to discuss how these limitations could 
have an impact on the overall findings. This current study is not without its limitations and the 
hope is that by highlighting them, future researchers can use these to modify their studies 
accordingly.  
 
A primary limitation of this study pertains to the generalizability of the findings. This study 
involved a convenience sample of patients with T2DM, obtained from outpatient clinics in western 
Pennsylvania. It is likely that our study population is not be representative of the T2DM population 
as a whole, missing relevant to sociodemographic characteristics. Additionally, the population was 
a newly diagnosed and relatively healthy cohort from a DM perspective. Therefore, the data is 
only representative of clinical outcome and comorbidity patterns early in the disease process. 
While comorbid depression and/or anxiety was not newly diagnosed, information on the severity 
of these diseases was not available. A host of other factors not available in the EMR may have also 
affected generalizability, such as heredity, lifestyle, health insurance, socioeconomic levels and 
medication adherence.  
 
The sample size also posed an additional challenge. Limited sample size in subgroup analyses led 
to reduced statistical power to detect relationships among variables. As this study was an 
exploratory study, it was decided to conduct such analyses regardless of sample size to assess 
numerical trends whenever possible. However, this greatly limits the impact of the results. 
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As a study using an EMR database, the possibility of misclassification bias is a considerable 
limitation, with errors in recording/coding having significant potential to affect the results. For 
instance, ICD-9-CM coding was relied upon to establish the index date of the study, which was a 
surrogate for the diagnosis of T2DM. In real clinical practice, the coding and diagnosis dates may 
not perfectly align. Additionally, although the EMR provided information regarding medications 
prescribed, information related to actual utilization of medications (proportions of prescriptions 
filled, proportions of prescriptions not filled, patient adherence) was not available. The degree to 
which medications discussed in this study were actually utilized cannot be clarified through the 
information present in the database.  
 
Despite these limitations, and even as an exploratory pilot study, this project has some merit. The 
current study included the addition of some variables that have not been formally investigated 
before in patients with T2DM. For example, defining severity through antidepressant dosage is 
newly applied strategy, to the best of our knowledge. Another study strength is the exploration of 
all important outcomes for T2DM patients including HgA1c, BG, blood pressure, LDL, total 
cholesterol and weight. Looking at all these outcomes simultaneously allows for a unique 
assessment of T2DM patients’ health. Finally, the simultaneous assessment of depression and 
anxiety allowed for useful comparisons and contrasts on which to build further research. 
VIII. Conclusion 
This current study supports continued special attention to T2DM patients with comorbid 
depression and/or anxiety. Several factors were predictive of overall HgA1c goal attainment in 
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T2DM patients and could be used to help healthcare professionals interpret and assess clinical 
outcomes in those patients.
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